SNPedia Links Results

Version 1.6.1
homehelpdownload: htmlcsvoutput: badgoodallformat: longshort 
/db/snp.dev/data/genome_Lilly_Mendel.txt (590991 SNP, 1062 displayed)
IDGTChrMag(Max)FreqGeneSummary
rs307377CT14.0 (4.0)5.13TAS1R3CC: common in complete genomics
CT: extra tasting ability?
TT: extra tasting ability?
rs138213197CT173.5 (3.5)0.13HOXB13CT: Significantly higher risk for prostate cancer in men
TT: Significantly higher risk for prostate cancer in men
rs6983267GG83.2 (3.2)26.93CCAT2GG: 1.6x increased risk for prostate cancer; also other cancers
GT: 1.3x risk of prostate cancer; aspirin reduces risk of colorectal cancer
TT: normal risk for cancers; aspirin reduces risk for colorectal cancer
rs72921001CC113.0 (3.0)41.37OR10A2AA: Least likely to think cilantro tastes like soap
AC: Less likely to think cilantro tastes like soap
CC: More likely to think cilantro tastes like soap
rs10033464GT43.0 (3.0)19.47GG: 0.92x decreased risk of Atrial Fibrillation and cardioembolic stroke.
GT: 1.28x increased risk of Atrial Fibrillation and cardioembolic stroke.
TT: 1.4x increased risk of Atrial Fibrillation and cardioembolic stroke
i5005436CT3.0 (3.0)62.76CC: normal
CT: miscallled by 23andMe, but should indicate being a carrier of allele for congenital adrenal hyperplasia
rs7755898CT63.0 (5.0)92.46CYP21A2CC: common in clinvar
CT: miscallled by 23andMe, but should indicate being a carrier of allele for congenital adrenal hyperplasia
TT: Congenital adrenal hyperplasia
rs6920220AG63.0 (3.5)29.70AA: 1.7x risk of Rheumatoid Arthritis
AG: 1.2x risk Rheumatoid Arthritis
GG: normal
rs4307059TT53.0 (3.0)40.31CC: Reduced Autism risk
CT: 1.19x risk of Autism
TT: 1.42x risk of Autism
rs1800497CC
GG
113.0 (4.0)63.36ANKK1CC: Normal (A2/A2): Better avoidance of errors. Normal OCD risk, normal Tardive Diskinesia risk, lower ADHD risk. Less Alcohol dependence. Higher risk of Postoperative Nausea. Lower obesity. Bupropion is effective.
CT: A1/A2: Bad at avoidance of errors. 0.5x lower OCD risk, 0.87x lower Tardive Diskinesia risk, higher ADHD risk. More Alcohol Dependence. Lower risk of Postoperative Nausea. Increased obesity. Bupropion is not effective.
TT: A1/A1: Bad at avoidance of errors. 0.25x lower OCD; 0.56x lower Tardive Diskinesia; higher ADHD; 1.4x Alcohol Dependence; lower Postoperative Nausea; Increased obesity; less pleasure response; Bupropion ineffective; 2.4x risk for adenoma recurrence.
rs6323TTX3.0 (3.0)19.42MAOAGG: Increased monoamine oxidase A activity
TT: reduced MAOA activity
rs53576AG32.8 (2.8)44.14OXTRAA: Lack of empathy?
AG: Lack of empathy?
GG: Optimistic and empathetic; handle stress well
rs1426654AA152.7 (2.7)90.11SLC24A5AA: probably light-skinned, European ancestry
AG: mixed African/European ancestry possible
GG: probably darker-skinned, Asian or African ancestry
rs13266634CT82.5 (3.0)41.39SLC30A8CC: increased risk for type-2 diabetes
CT: increased risk for type-2 diabetes
TT: Normal risk for type-2 diabetes
rs12803066AG112.5 (2.5)25.80CNTN5AG: increased risk of myopia
rs12340895CG92.5 (3.5)39.29JAK2CG: Increased odds (2 fold?) of developing V617F-positive MPN
GG: 2 - 4 fold increased odds of developing V617F-positive MPN
rs11672691GG192.5 (2.5)52.79SLC26A6AG: 1.18x increased risk for PCSM in patients with prostate cancer
GG: 1.39x increased risk for PCSM in patients with prostate cancer
rs11209026AG12.5 (3.0)11.77IL23RAA: 0.26x lower risk for certain autoimmune diseases.
AG: 0.26x lower risk for certain autoimmune diseases.
GG: Normal, but higher risk for certain autoimmune diseases.
rs10974944CG92.5 (3.0)39.39JAK2CG: Increased odds (2 - 4 fold?) of V617F-associated MPNs
GG: 2 - 4 fold increased odds of V617F-associated MPNs
rs10821936CC102.5 (2.5)12.91ARID5BCC: Higher risk of childhood acute lymphoblastic leukemia
CT: Higher risk of childhood acute lymphoblastic leukemia
TT: normal
rs10484554CT62.5 (2.5)24.11CC: common
CT: 2.8x increased risk for psoriasis
TT: ~4x increased risk for psoriasis
rs9939609AT162.5 (3.1)45.30FTOAA: obesity risk and 1.6x risk for T2D
AT: 1.3x risk for T2D; obesity risk
TT: lower risk of obesity and Type-2 diabetes
rs7574865GT22.5 (3.5)37.76STAT4GG: normal risk of rheumatoid arthritis, SLE, Sj÷gren's syndrome, type-1 diabetes, and primary biliary cirrhosis.
GT: 1.3x risk of rheumatoid arthritis; 1.55x risk of SLE; 1.42x risk of Sj÷gren's syndrome; increased risk of type-1 diabetes; and increased risk of primary biliary cirrhosis.
TT: 2.6x risk of rheumatoid arthritis; 3.10x risk of SLE; 2.28x risk of Sj÷gren's syndrome; increased risk of type-1 diabetes; and increased risk of primary biliary cirrhosis.
rs6441286GG32.5 (2.5)16.73IL12A-AS1GG: 3.08x chance of developing primary biliary cirrhosis
GT: 1.54x chance of developing primary biliary cirrhosis.
TT: Normal chances of developing primary biliary cirrhosis
rs4570625GG122.5 (2.5)58.67TPH2GG: higher scores on anxiety-related personality traits; greater placebo response
GT: normal
TT: normal
rs3780374AG92.5 (2.8)39.70JAK2AA: Substantially increased odds of developing V617F-positive MPN.
AG: Substantially increased odds of developing V617F-positive MPN.
rs2943634CC22.5 (2.5)47.31AA: lower risk of ischemic stroke
CC: higher risk of ischemic stroke
rs2910164CC52.5 (2.5)7.85MIR146ACC: higher cancer risk ? (ambiguous flip)
CG: higher/earlier cancer likelihood??
GG: normal
rs2802292TT62.5 (2.5)36.23FOXO3GG: 1.5x~2.7x more likely to live to 100.
GT: One copy of longevity gene. Slightly increased lifespan.
TT: Less likely to live to 100.
rs2180439CT202.5 (3.0)47.78CC: Reduced risk of Male Pattern Baldness.
CT: Increased risk of Male Pattern Baldness.
TT: 2x increased risk of Male Pattern Baldness.
rs1121980CT
AG
162.5 (3.0)45.99FTOCC: average
CT: 1.67x risk for obesity
TT: 2.76x risk for obesity
rs1061170CT12.5 (3.2)46.61CFHCC: 5.9x risk for AMD; higher mortality among nonagenarians
CT: 2.5x risk for AMD; higher mortality among nonagenarians
TT: common/normal
rs795484AA
TT
122.5 (2.5)9.85TAOK3AA: Even more increased morphine dose requirement and postoperative pain in tonsillectomy and adenoidectomy
AG: Increased morphine dose requirement and postoperative pain in tonsillectomy and adenoidectomy
GG: Normal morphine dose requirement and postoperative pain in tonsillectomy and adenoidectomy
rs664143CT
AG
112.5 (2.5)46.74ATMCC: normal
CT: Higher risk for number of cancers
TT: Higher risk for number of cancers
rs613872GT182.5 (2.5)27.54TCF4GG: ~20-30x higher risk for Fuchs' dystrophy, a corneal disorder
GT: ~5 fold higher risk for Fuchs' dystrophy, a corneal disorder
TT: common in complete genomics
rs3825942CC
GG
152.3 (2.3)68.76LOXL1CC: common but 10x higher glaucoma risk in most (but not all) populations
CT: possibly lower glaucoma risk?
TT: 10x to 27x lower risk of exfoliation glaucoma
rs1815739TT112.3 (2.3)22.58ACTN3CC: Better performing muscles. Likely sprinter.
CT: Mix of muscle types. Likely sprinter.
TT: Impaired muscle performance. Likely endurance athlete.
rs662AA
TT
72.3 (2.3)48.03PON1AA: higher risk of of coronary heart disease
AG: 0.65x lower risk of ovarian cancer; higher risk of coronary heart disease in some studies; somewhat reduced PON catalytic efficiency
GG: protective against coronary heart disease in some studies
rs2165241CT152.2 (2.3)50.59LOXL1CC: normal
CT: 4.4x increased risk of exfoliation glaucoma
TT: >10x increased risk of exfoliation glaucoma
rs1837253CT52.2 (2.8)38.54TSLPCC: normal/common in clinvar
CT: reduced risk (0.84x) for late-onset (adult) asthma
TT: reduced risk (0.73) for late-onset (adult) asthma
rs1136287TT172.2 (2.2)40.64SERPINF1CC: normal
CT: 1.5x increased risk of wet ARMD
TT: 3.9x increased risk of wet ARMD
rs17077540AG182.1 (2.1)21.24LOC643542AA: common in complete genomics
AG: 1.6x major depressive disorder risk
GG: 1.6x major depressive disorder risk
rs9273363CC62.1 (2.1)56.23HLA-DQB1AA: Higher risk of Type 1 Diabetes.
AC: Lower 0.87x risk of Type 1 Diabetes.
CC: Much lower 0.15x risk of Type 1 Diabetes.
rs9264942CT62.1 (2.2)48.28RPL3P2CC: 90% reduction in HIV viral load
CT: 60% reduction in HIV viral load
TT: normal
rs8050894CC162.1 (2.1)34.56VKORC1CC: warfarin sensitivity (~2.5 mg/day)
CG: average warfarin response (~5 mg/day)
GG: warfarin resistance (~6.5 mg/day)
rs7837688GG82.1 (2.1)82.09GG: 1.7x increased risk for prostate cancer
GT: 1.7x increased risk for prostate cancer
TT: normal risk
rs5751876TT222.1 (2.1)18.55ADORA2ACC: None
CT: None
TT: significantly higher anxiety levels after moderate caffeine consumption
rs4430796AA172.1 (2.1)28.66HNF1BAA: 1.38x increased risk for prostate cancer
AG: normal risk
GG: normal risk
rs3775291AG
CT
42.1 (2.2)42.39TLR3AA: 0.44x decreased risk for dry age related macular degeneration
AG: 0.71x decreased risk for dry age related macular degeneration
GG: common but higher risk of age related macular degeneration
rs1801131AC
GT
12.1 (2.5)43.02MTHFRAC: Possible risks. Complex.
CC: Number of risks. Complex.
rs1800955CT112.1 (2.1)69.48DRD4CC: increased susceptibility to novelty seeking
CT: increased susceptibility to novelty seeking
TT: normal
rs1667394AA
TT
152.1 (2.1)58.99HERC2AA: blond hair & blue eyes is 4x more likely
GG: darker skin, eye and hair color is more likely
rs1329428GG
CC
12.1 (2.1)32.75CFHAA: normal
AG: ?
GG: 2x increased risk for macular degeneration
rs944289CT142.1 (2.2)50.97CT: 1.3x increased thyroid cancer risk
TT: 2.6x increased thyroid cancer risk
rs807701CC
GG
62.1 (2.1)13.46DCDC2CC: 2-5x increased dyslexia risk
CT: Slightly increased dyslexia risk
TT: Normal dyslexia risk
rs762551AC152.1 (2.5)42.64CYP1A2AA: Fast Caffeine Metabolizer.
AC: Carrier of one CYP1A2*1F allele; Slow Caffeine Metabolizer.
CC: CYP1A2 slow caffeine metabolizer.
rs738409GG
CC
222.1 (3.1)56.92PNPLA3CC: higher odds of alcoholic liver disease, increased liver fat
CG: increased liver fat, odds of alcoholic liver disease
GG: most common genotype; slightly less damage from alcohol
rs708272CT
AG
162.1 (2.2)50.28CETPCC: No benefit to alcohol consumption
CT: No reduction in heart disease risk from drinking alcohol
TT: B2B2 genotype; some reduction in heart disease risk from moderate alcohol consumption
rs664677CT112.1 (2.1)46.39ATMCC: Lower lung cancer and increased breast cancer risk
CT: Lower lung cancer and increased breast cancer risk
rs646776AA
TT
12.1 (2.1)60.49CELSR2AA: 1.2x risk of coronary artery disease
rs560887GG
CC
22.1 (2.1)53.91G6PC2AA: Avg. fasting Plasma Glucose 5.06 mmol/L (91 mg/dl).
AG: Avg. fasting Plasma Glucose 5.12 mmol/L (92 mg/dl).
GG: Avg. fasting Plasma Glucose 5.18 mmol/L (93 mg/dl).
rs543749GG202.1 (2.1)74.81ADAM33GG: if a smoker, somewhat more likely to develop COPD
rs5443CT122.1 (2.4)42.45GNB3CC: normal, but higher risk for several conditions
CT: some risk
TT: viagra is more likely to have an effect. increased metabolic disease risk.
rs1695GG112.1 (2.1)11.15GSTP1AA: normal asthma risk in certain populations
AG: ?
GG: 3.5x asthma risk in certain populations
rs33977706TT
AA
162.0 (2.0)7.02SOCS1TT: Lower body mass index
rs17822931CT162.0 (2.5)23.17ABCC11CC: Wet earwax. Normal body odour. Normal colostrum.
CT: Wet earwax. Slightly better body odour.
TT: Dry earwax. No body odour. Likely Asian ancestry. Reduced colostrum.
rs17782313CT182.0 (2.5)35.50MC4RCC: adults likely to be 0.44 BMI units higher
CT: adults likely to be 0.22 BMI units higher
TT: normal
rs17672135TT12.0 (2.0)79.26FMN2CC: normal
CT: Reduced risk (0.7x) for heart disease
TT: 1.3x risk
rs17070145CT52.0 (2.1)44.90WWC1CC: reduced memory abilities
CT: increased memory performance
TT: greatly increased memory performance
rs13277113AA82.0 (2.0)8.64
rs13254738AC82.0 (2.0)44.35PRNCR1AC: 1.18x prostate cancer risk
CC: 1.18x prostate cancer risk
rs13153971CT52.0 (2.0)48.65SLC6A7CC: 1.58x higher risk of Asthma.
CT: Normal (higher) risk of Asthma.
TT: Lower 0.63x risk of Asthma.
rs12913832GG152.0 (2.0)46.15HERC2AA: brown eye color, 80% of the time
AG: brown eye color
GG: blue eye color, 99% of the time
rs12248560CT102.0 (2.0)33.65CYP2C19CC: normal
CT: CYP2C19*17 ultra fast metabolizer; drug metabolism effects; also 0.77x decreased breast cancer risk
TT: CYP2C19*17 ultra fast metabolizer; drug metabolism effects; also 0.77x decreased breast cancer risk
rs11190870CT102.0 (2.5)48.84CT: Possibly increased risk of scoliosis
TT: Possibly even more increased risk of scoliosis
rs11045585AA122.0 (2.0)73.46SLCO1B3AA: 24% chance (lower than average) of docetaxel-induced leukopenia/neutropenia
AG: 63% chance (higher than average) of docetaxel-induced leukopenia/neutropenia
GG: (no data; implied high chance of docetaxel-induced leukopenia/neutropenia)
rs10993994TT102.0 (2.0)18.03MSMBCT: increased prostate cancer risk (odds ratio 1.2)
TT: increased prostate cancer risk (odds ratio 1.6)
rs10984447AA92.0 (2.0)59.59DBC1AA: >1.17x increased risk for multiple sclerosis
AG: 1.17x increased risk for multiple sclerosis
GG: Normal risk for multiple sclerosis
rs10936599CC32.0 (2.0)55.83MYNNCC: longer telomeres, longer life?
TT: shorter telomeres, shorter life?
rs10889677CC12.0 (2.0)45.21IL23RAA: 1.5x increased risk for certain autoimmune diseases
AC: 1.5x increased risk for certain autoimmune diseases; 2x increased risk for Graves disease
CC: 1x increased risk for certain autoimmune diseases; 2.3x increased risk for Graves disease
rs10871777AG182.0 (2.1)35.40MC4RAA: normal
AG: adults likely to be 0.22 BMI units higher
GG: adults likely to be 0.44 BMI units higher
rs10811661CT92.0 (2.1)27.51CC: normal
CT: 1.2x increased risk for type-2 diabetes
TT: 1.2x increased risk for type-2 diabetes
rs10784502CC122.0 (2.0)18.69HMGA2CC: better intracranial volume?
CT: Slightly higher intracranial volume
TT: less intracranial volume?
rs10494366TT12.0 (2.0)36.82NOS1APGG: Long QT interval
GT: average QT interval
TT: Shorter QT interval
rs10455872AG62.0 (2.1)9.99LPAAG: increased Coronary Heart disease risk
GG: increased Coronary Heart disease risk
rs10306114AG92.0 (3.0)12.85PTGS1AA: normal
AG: Higher risk of bleeding during coronary angiography
GG: Higher risk of bleeding during coronary angiography
rs9954153GT182.0 (2.0)25.78GG: ~5x higher risk for Fuchs' dystrophy, a corneal disorder
GT: ~2.5x higher risk for Fuchs' dystrophy, a corneal disorder
TT: common
rs9652490AA152.0 (2.0)61.80LINGO1AA: ~2x increased risk for Parkinson's disease, and, essential tremor
AG: Slightly increased risk of developing Parkinson's Disease
GG: Normal risk of developing Parkinson's Disease
rs9340799AA62.0 (3.0)42.96ESR1AA: Women have lower risk of Endometriosis but normal risk for Endometrial Cancer, and more cognitive impairment with age.
AG: Women have normal (lower) risk of Endometriosis, 0.75x lower risk of Endometrial Cancer, and normal (higher) risk of cognitive impairment.
GG: Women have 10x risk of Endometriosis, but half the risk of Endometrial Cancer and 0.76x less cognitive impairment.
rs9303277TT172.0 (2.0)25.05IKZF3CC: Normal risk of developing primary biliary cirrhosis
CT: Slightly increased risk of developing primary biliary cirrhosis
TT: Increased risk of developing primary biliary cirrhosis
rs8085664AC182.0 (2.1)40.35SLC14A2AA: 0.61x reduced risk of Male Pattern Baldness.
AC: 0.78x reduced risk of Male Pattern Baldness.
CC: Normal (higher) risk of Male Pattern Baldness.
rs7923837GG102.0 (2.0)36.88AA: normal risk for T2D
AG: 1.6x risk for T2D
GG: 3.2x risk for T2D
rs7903146CC102.0 (3.5)52.97TCF7L2CC: Normal (lower) risk of Type 2 Diabetes and Gestational Diabetes.
CT: 1.4x increased risk for diabetes (and perhaps colon cancer).
TT: 2x increased risk for Type-2 diabetes
rs7807268CG72.0 (2.0)47.81CC: 1.4x risk for Crohn's disease
CG: 1.3x risk for Crohn's disease
GG: normal
rs7743761AC62.0 (2.0)40.93DHFRP2AA: 20x increased risk of Ankylosing Spondylitis.
AC: 4.6x increased risk of Ankylosing Spondylitis.
CC: Normal (lower) risk of Ankylosing Spondylitis.
rs7639618CT32.0 (2.0)29.87DVWACC: normal
CT: 1.45x increased osteoarthritis risk
TT: 1.45x increased osteoarthritis risk
rs7442295AA42.0 (2.0)58.01SLC2A9AA: ~4x higher risk for hyperuracemia
AG: ~2x higher risk for hyperuracemia
GG: normal
rs7221412AG172.0 (2.0)50.59TRNAS6AA: Early riser. Wakes up 1 hour earlier than those with GG genotype.
AG: Intermediate riser. Wakes up at a time between the AA and GG genotypes.
GG: Late riser. Wakes up 1 hour later than those with AA genotype.
rs7216389CC172.0 (2.0)22.98GSDMBCC: 0.69x lower risk of Childhood Asthma.
CT: Normal risk for Childhood Asthma.
TT: 1.5x increased risk for Childhood Asthma.
rs6997709GT82.0 (2.0)39.35GG: 1.5x higher risk for hypertension
GT: 1.2x higher risk for hypertension
TT: normal
rs6897932CC52.0 (2.0)57.92IL7RCC: 1.5x increased risk for multiple sclerosis
CT: 1.3x increased risk for multiple sclerosis
TT: normal
rs6855911AA42.0 (2.0)53.08SLC2A9AA: normal, but increased risk of gout
AG: 0.62x decreased risk for gout
GG: rare, but 0.62x decreased risk for gout
rs6807362CC32.0 (2.0)28.13HTR3CCC: increased autism risk
CG: normal autism risk
GG: decreased autism risk
rs6732426CC22.0 (2.0)27.51THADACC: curlier hair
TT: straighter hair
rs6700998GG12.0 (2.0)32.02GG: 0.83x reduced risk of Atopic Dermatitis.
GT: Normal risk of Atopic Dermatitis.
TT: 1.2x increased risk of Atopic Dermatitis.
rs6495306GG152.0 (2.0)13.98CHRNA5
rs6457617CT62.0 (2.1)50.28CC: normal
CT: 2.3x risk of rheumatoid arthritis
TT: 5.2x risk of rheumatoid arthritis
rs4779584CT152.0 (2.0)32.81CC: average
CT: 1.23x risk for colorectal cancer
TT: 1.70x risk for colorectal cancer
rs4506565AA102.0 (2.0)49.19TCF7L2AA: 1.9x increased risk for type-2 diabetes
AT: 1.4x increased risk for type-2 diabetes
TT: normal
rs4481887AG12.0 (2.0)36.30AA: most likely to smell asparagus metabolites in urine
AG: more likely to be able to smell asparagus metabolites in urine
GG: least likely to be able to smell asparagus metabolites in urine
rs4420638AG192.0 (3.0)27.45APOC1AA: Normal/Average risk for Alzheimer's
AG: ~3x increased Alzheimer's risk; 1.4x increased heart disease risk ; increased LDL cholesterol
GG: 2x+ increased Alzheimer's risk, further genotyping suggested ; increased LDL cholesterol
rs4402960GT32.0 (2.1)43.14IGF2BP2GG: normal
GT: 1.2x increased risk for type-2 diabetes
TT: 1.2x increased risk for type-2 diabetes
rs4149268GG
CC
92.0 (2.0)39.18ABCA1AG: associated with higher HDL cholesterol
GG: associated with higher HDL cholesterol
rs4027132AA22.0 (2.0)30.01AA: 1.51x increased risk of developing bipolar disorder
AG: 1.39x increased risk of developing bipolar disorder
GG: Normal risk of developing bipolar disorder
rs3842787CT92.0 (3.0)12.93PTGS1CC: normal
CT: Higher risk of bleeding during coronary angiography
TT: Higher risk of bleeding during coronary angiography
rs3821236AG22.0 (2.1)34.09STAT4AA: 2x higher risk of lupus
AG: 1.4x higher risk of lupus
GG: normal
rs3819331TT112.0 (2.0)72.13PTSCC: increased risk of autism
CT: increased risk of autism
TT: lower risk of autism
rs3790844CC
GG
12.0 (2.0)6.76NR5A2CC: reduced risk (0.59x) of pancreatic cancer
CT: slightly reduced risk (0.77x) for pancreatic cancer
TT: common/normal
rs3738919AC22.0 (2.5)46.65ITGAVAA: Normal risk of developing rheumatoid arthritis
AC: 1.94x risk of developing rheumatoid arthritis
CC: 1.94x risk of developing rheumatoid arthritis
rs3184504CT122.0 (3.0)44.77SH2B3CC: normal
CT: increased risk for celiac disease
TT: increased risk for celiac disease
rs3135391CT
AG
62.0 (3.0)20.23HLA-DRACC: normal
CT: HLA-DRB1*1501 carrier; higher multiple sclerosis risk
TT: 3 to 6 fold higher risk for multiple sclerosis
rs3129934CT62.0 (2.2)26.86C6orf10CC: Normal lower risk of Multiple Sclerosis.
CT: Increased risk of Multiple Sclerosis.
TT: 3.3x increased risk for multiple sclerosis
rs2908004CC
GG
72.0 (2.0)30.64WNT16CC: weaker bones
TT: stronger bones
rs2811712AA92.0 (2.1)77.62CDKN2BASAA: Normal (higher) risk of physical impairment with age.
AG: 1.5x less risk for physical impairment with age.
GG: >1.5x less risk for physical impairment with age.
rs2736990CC
GG
42.0 (2.0)22.10SNCACC: Increased risk of developing Parkinson's Disease
CT: Slightly increased risk of developing Parkinson's Disease
TT: Normal risk of developing Parkinson's Disease
rs2736340TT82.0 (2.0)8.83
rs2707466GG
CC
72.0 (2.0)29.68WNT16AA: stronger bones
GG: weaker bones
rs2542052CC112.0 (2.0)35.67APOC3CC: better odds of living to 100
rs2395185GG62.0 (3.0)47.09GG: 1.33x increased risk of Ulcerative Colitis, but much lower Type 1 Diabetes risk.
GT: 2.72x higher risk of Type 1 Diabetes, but 0.88x lower risk of Ulcerative Colitis.
TT: 9.49x risk of Type 1 Diabetes, but 0.58x lower risk of Ulcerative Colitis.
rs2352028CT132.0 (2.0)36.68GPC5TT: Increased risk of lung cancer in non-smokers and never smokers
rs2300478GG22.0 (2.0)5.13MEIS1GG: >1.7x risk for developing restless legs syndrome
GT: 1.7x risk for developing restless legs syndrome
TT: Normal risk of developing restless legs syndrome
rs2274223AG102.0 (2.0)46.62PLCE1AA: normal
AG: 1.5x increased risk for stomach & esophageal cancer (seen in Han Chinese)
GG: 1.9x increased risk for stomach & esophageal cancer (seen in Han Chinese)
rs2241880CC
GG
22.0 (2.0)27.99ATG16L1CC: 2x-3x increased risk for Crohn's disease in Caucasians
CT: 1.4x increased risk for Crohn's disease in Caucasians
TT: normal
rs2235040GG
CC
72.0 (2.0)76.83ABCB1AA: 7x more likely to respond to certain antidepressants
AG: 7x more likely to respond to certain antidepressants
GG: 7x less likely to respond to certain antidepressants
rs2201841TT
AA
12.0 (2.0)45.34IL23RCC: 1.5x increased risk for Crohn's disease
CT: 1.5x increased risk for Crohn's disease; 2x increased risk for Graves' disease
TT: 2.4x increased risk for Graves' disease
rs2171492TT72.0 (2.0)14.74CPA4TT: Higher prostate cancer risk
rs2156921GG222.0 (2.0)19.80BCRAA: normal risk for depression
AG: 1.29x increased risk for depression
GG: 1.29x increased risk for depression
rs2108622CC192.0 (2.0)50.72CYP4F2CC: lower warfarin dosing
CT: None
TT: higher warfarin dosing
rs2073963GT72.0 (2.5)46.46HDAC9GG: increased risk of baldness
GT: increased risk of baldness
TT: reduced risk of baldness
rs2073711CT
AG
152.0 (2.0)45.67CILPCC: Back Pain: normal (higher) risk of Lumbar Disc Disease.
CT: Back Pain: lower risk of Lumbar Disc Disease.
TT: Back Pain: lower risk of Lumbar Disc Disease.
rs2032583TT
AA
72.0 (2.0)76.82ABCB1CC: 7x more likely to respond to certain antidepressants.
CT: 7x more likely to respond to certain antidepressants.
TT: 7x less likely to respond to certain antidepressants.
rs1858830CC72.0 (2.0)77.91METCC: 2x risk of autism
CG: 1.6x increased autism risk
GG: normal
rs1801260CT
AG
42.0 (2.0)39.95CLOCKCC: Lower ADHD symptom scores.
CT: Normal (higher) risk of ADHD symptoms.
TT: Normal (higher) risk of ADHD symptoms.
rs1800896AG
CT
12.0 (2.0)48.28IL10AA: 1.8x increased prostate cancer risk
AG: 1.6x increased prostate cancer risk
GG: Normal prostate cancer risk
rs1800888CT52.0 (2.5)1.82ADRB2CC: normal
CT: increased risk of coronary artery disease
TT: increased risk of coronary artery disease
rs1799990AG202.0 (2.0)41.70PRNPAA: Increased chance of Prion Disease (PrP 129 Met homozygote)
AG: Resistance to Prion Disease (PrP 129 Met/Val heterozygote)
GG: normal
rs1799884GG
CC
72.0 (3.0)68.25GCKAA: 2.7x increased risk for Type 2 Diabetes. Mothers have babies 54g heavier.
AG: 1.3x increased risk for Type 2 Diabetes. Mothers have babies 27g heavier.
GG: Mothers have typical Birth-Weight babies. Slightly lower risk of Type 2 Diabetes.
rs1734791AAX2.0 (2.0)27.58MECP2AA: 1.4x increased risk for lupus
AT: 1.4x increased risk for lupus
TT: normal
rs1711437AA
TT
112.0 (2.4)20.09MMP20AA: younger, healthier kidney function
AG: younger, healthier kidney function
GG: slightly reduced creatinine clearance
rs1676486AG12.0 (2.0)30.31COL11A1AA: >1.4x risk for LDH
AG: 1.4x risk for LDH
rs1585215AG
CT
42.0 (2.1)41.98NFKB1AA: normal
AG: 2x increased risk for Hodgkin lymphoma
GG: 3.5x increased risk for Hodgkin lymphoma
rs1454292CC82.0 (2.0)18.62RSL24D1P7CC: curlier hair
TT: straighter hair
rs1385699TTX2.0 (2.0)25.00EDA2RCC: slightly less likely to go bald
CT: ?
TT: increased risk of baldness
rs1375144CC
GG
22.0 (2.0)13.16DPP10CC: 1.59x increased risk of developing bipolar disorder
CT: 1.32x increased risk of developing bipolar disorder
TT: Normal risk of developing bipolar disorder
rs1265181CG62.0 (2.5)29.56CC: normal
CG: increased risk for psoriasis
GG: possibly increased risk of psoriasis
rs1160312GG202.0 (2.0)26.80C19orf26AA: 1.6x increased risk of Male Pattern Baldness.
AG: 1.6x increased risk of Male Pattern Baldness.
GG: Reduced risk of Baldness.
rs1135840CC
GG
222.0 (2.0)26.54CYP2D6CC: Homozygous for CYP2D6 variants (non-CYP2D6*1)
CG: Carrier of at least one CYP2D6 variants (non-CYP2D6*1)
GG: normal
rs1065852CT
AG
222.0 (3.2)33.69CYP2D6CC: normal
CT: Carrier of one CYP2D6 decreased or non-functioning variant.
TT: Homozygous for CYP2D6 decreased or non-functioning variants.
rs1051730CC
GG
152.0 (2.5)45.65CHRNA3CC: Smokes normal (lower) number of cigarettes if a smoker.
CT: 1.3x increased risk of lung cancer
TT: 1.8x increased risk of lung cancer; reduced response to alcohol, therefore possibly increased risk of alcohol abuse
rs1050631CT
AG
182.0 (2.1)44.99SLC39A6CC: Mean Survival Time of 32 months for esophageal squamous-cell carcinoma
CT: Mean Survival Time of 25 months for esophageal squamous-cell carcinoma
TT: Mean Survival Time of 17 months for esophageal squamous-cell carcinoma
rs1050565GG
CC
172.0 (2.0)10.85BLMHAA: normal
AG: normal
GG: if testicular cancer patient, 5x poorer response to bleomycin chemotherapy
rs1050152CT52.0 (2.1)43.64SLC22A4CC: normal
CT: 2.1x increased risk of Crohn's disease
TT: 2.1x increased risk of Crohn's disease
rs1045642CT
AG
72.0 (3.0)50.59ABCB1CC: increased risk of cannabis dependence, lower (normal) cancer risk
CT: Slower metaboliser for some drugs
TT: altered drug metabolism and bioavailability; moderately increased risk for certain cancers
rs1042522CG172.0 (3.0)40.08TP53CC: Live 3 years longer. Chemotherapy is more effective.
CG: Slightly increased lifespan?
GG: Common variant. Slightly shorter lifespan.
rs1024611CT
AG
172.0 (2.2)40.45CCL2CC: increased risk of exercise induced ischemia, Increased CCL2 levels; increased rate of HIV progression
CT: increased risk of exercise induced ischemia
TT: normal risk
rs1015362GG
CC
202.0 (2.0)51.47AA: Probably tans instead of freckles and sunburns.
AG: 2-4x higher risk of sun sensitivity if part of risk haplotype.
GG: 2-4x higher risk of sun sensitivity if part of risk haplotype.
rs987525AA82.0 (2.0)5.76AA: 6x increased risk for cleft lip
AC: 2.5x increased risk for cleft lip
CC: normal
rs965513AG92.0 (2.0)42.64AA: 3.5x increased thyroid cancer risk
AG: 1.7x increased thyroid cancer risk
GG: normal
rs800292CC
GG
12.0 (2.0)55.85CFHCC: 5% higher risk of Age related macular degeneration
CT: 1% decreased risk of macular degeneration
TT: 5% decreased risk of macular degeneration
rs763110CT12.0 (2.0)45.19FASLGCC: normal
CT: ~0.80x reduced cancer risk
TT: ~0.80x reduced cancer risk
rs744373CT
AG
22.0 (2.0)42.86CC: 1.17x risk of Alzheimer's
CT: 1.17x risk of Alzheimer's
TT: Normal
rs688034TT222.0 (2.0)8.71SEZ6LCC: normal
CT: 1.1x risk higher risk for coronary artery disease
TT: 1.6x risk
rs663048GT222.0 (2.5)33.76SEZ6LGG: Normal risk of developing lung cancer
GT: Significantly increased risk of developing lung cancer
TT: 3x increased risk of developing lung cancer
rs629242CT42.0 (2.1)35.32KIAA1211CC: normal risk
CT: somewhat higher risk for prostate cancer
TT: somewhat higher risk for prostate cancer
rs622342CC62.0 (2.0)12.05SLC22A1CC: influences dosage for Parkinson's patients
rs505922TT92.0 (2.1)41.77ABOCC: blood type is not O, increased risk for some diseases.
CT: 1.2x risk of pancreatic cancer
TT: blood type O
rs499697TT
AA
12.0 (2.0)54.01TT: straighter hair
rs460000CC
GG
52.0 (2.0)58.27SLC6A3CC: Better response to amphetamine
rs383830AA
TT
52.0 (2.0)66.48AA: 1.9x risk
AT: 1.6x risk
TT: normal
rs358806CC32.0 (2.0)66.31AA: Normal risk of developing Type-2 diabetes
AC: 0.86x increased risk of developing Type-2 diabetes
CC: 1.78x increased risk of developing Type-2 diabetes
rs189798CT
AG
82.0 (2.1)44.33CC: normal high myopia risk
CT: decreased high myopia risk
TT: decreased high myopia risk
rs27072CC52.0 (2.0)67.15SLC6A3CC: 2x risk of severe alcohol withdrawal. Possible increased odds of ADHD.
CT: Lower risk of alcohol withdrawal seizures, and perhaps lower odds of ADHD.
TT: Lower risk of alcohol withdrawal seizures, and probably lower odds of ADHD.
rs25487AG
CT
192.0 (2.0)47.49XRCC1AA: 0.7x lower risk for skin cancer
AG: 2x higher risk for skin cancer; possibly other cancers
GG: 2x higher risk for skin cancer; possibly other cancers
rs6311CT132.0 (3.0)46.70HTR2ACC: 3.6x increased risk of sexual dysfunction when taking SSRI Antidepressants.
CT: Normal risk of sexual dysfunction when taking SSRI Antidepressants.
TT: Normal (lower) risk of sexual dysfunction when taking SSRI Antidepressants.
rs5918CT172.0 (2.0)23.73ITGB3CC: MI risk, aspirin resistance
CT: MI risk, aspirin resistance
TT: average
rs5882AA162.0 (2.1)44.40CETPAA: Faster aging. Increased risk for Dementia. Less good cholesterol.
AG: Lower risk of dementia and Alzheimer's disease. Higher good cholesterol.
GG: Longer lifespan, 0.28x lower risk of dementia, 0.31x lower risk of Alzheimer's.
rs5174AA
TT
12.0 (2.0)14.97LRP8AA: 1.3x increased risk for heart disease
AG: 1.3x increased risk for heart disease
GG: Normal risk for heart disease
rs4961GT42.0 (2.1)30.97ADD1GG: normal
GT: 1.8x increased risk for high blood pressure
TT: 1.8x increased risk for high blood pressure
rs4633CT222.0 (2.0)50.44COMTCC: normal
CT: higher risk for endometrial cancer
TT: higher risk for endometrial cancer
rs4585GT112.0 (2.0)47.42ATMGG: slightly higher (1.35x) odds of good metformin response in type 2 diabetics
GT: average response to metformin in type 2 diabetics
TT: slightly poorer (0.75x) response to metformin in type 2 diabetics
rs671GG122.0 (4.0)98.56ALDH2AA: Asian Flusher; increased risk of esophageal cancer; East Asian ancestry; Disulfiram not effective for alcoholism.
AG: Asian Flush; worse hangovers; increased risk of esophageal cancer; East Asian ancestry; Disulfiram probably not effective for alcoholism.
GG: Alcohol Flush: Normal, doesn't flush. Normal hangovers. Normal risk of Alcoholism. Normal risk of Esophageal Cancer. Disulfiram is effective for alcoholism.
rs326AA82.0 (2.0)48.84LPLAA: lower HDL cholesterol
AG: lower HDL cholesterol
GG: normal risk
rs10757278AA91.9 (2.5)28.38AA: 0.78x reduced risk for Coronary Heart Disease. 0.77x reduced risk for Brain Aneurysm and Abdominal Aortic Aneurysm.
AG: 1.3x risk for Heart Attack. Normal risk for Abdominal Aortic Aneurysm and Brain Aneurysm.
GG: 1.6x risk for Heart Attack; 1.3x risk for Abdominal Aortic Aneurysm and Brain Aneurysm.
rs7927894CT111.9 (2.0)45.11CC: 1.2x higher risk of Atopic Dermatitis.
CT: Normal risk of Atopic Dermatitis.
TT: 0.83x lower risk of Atopic Dermatitis.
rs4950928CC11.9 (2.0)63.05CHI3L1CC: Normal (higher) risk of Asthma.
CG: Half the risk (maybe) of Asthma.
GG: Half the risk (maybe) of Asthma.
rs2303138GG51.9 (2.0)82.34LNPEPAA: 2.25x increased risk (0.2%) for Ankylosing Spondylitis.
AG: 1.5x increased risk (0.15%) for Ankylosing Spondylitis.
GG: Normal risk (0.1%) for Ankylosing Spondylitis.
rs2200733CC41.9 (2.2)74.98LOC729065CC: 0.86x decreased risk of Atrial Fibrillation
CT: 1.4x increased risk of Atrial Fibrillation and ischemic stroke.
TT: 1.5x increased risk of Atrial Fibrillation and ischemic stroke.
rs776746GG
CC
71.9 (1.9)82.65CYP3A5AA: reference allele
AG: carrier of 1 nonfunctional CYP3A5 allele; drug metabolism affects
GG: Nonfunctional CYP3A5; drug metabolism effects; common
rs721048AA21.9 (1.9)3.63EHBP1AA: slightly increased prostate cancer risk
AG: None
GG: normal
rs7538876AG11.8 (2.1)46.18PADI6AA: 1.28x increased Basal Cell Carcinoma risk.
AG: Normal risk of Basal Cell Carcinoma.
GG: 0.78x decreased Basal Cell Carcinoma risk.
rs4474514AA121.8 (1.8)61.84KITLGAA: >3x increased testicular cancer risk for men
AG: 3x increased testicular cancer risk for men
GG: normal
rs3135388CT
AG
61.8 (2.0)20.41HLA-DRACC: normal
CT: 3x higher risk of multiple sclerosis
TT: 3-6x higher risk of multiple sclerosis
rs2003046CC11.8 (2.0)58.99C1orf127AA: 0.57x lower risk of Male Pattern Baldness.
AC: 0.75x lower risk of Male Pattern Baldness.
CC: Normal (higher) risk of Male Pattern Baldness.
rs801114GT11.8 (2.1)44.67GG: 1.28x increased Basal Cell Carcinoma risk.
GT: Normal (slightly higher) risk of Basal Cell Carcinoma.
TT: 0.78x decreased Basal Cell Carcinoma risk.
rs37973AG71.8 (2.3)47.96GLCCI1AA: normal
AG: Among asthmatics, 1.5x more likely to show less response to inhaled glucocorticoids
GG: Among asthmatics, 2.3x more likely to show less response to inhaled glucocorticoids
rs9275596CT61.7 (3.0)44.30LOC100507686CC: 3x increased risk for developing a peanut allergy
CT: 1.7x increased risk for developing a peanut allergy
TT: common/normal
rs8055236GG161.7 (1.7)65.44CDH13GG: common, but 2.2x higher risk for heart disease
GT: 1.9x risk
TT: normal
rs4132601GT71.7 (2.4)37.95IKZF1GG: moderately (~2.5x) increased risk for acute lymphoblastic leukemia
GT: somewhat (1.7x) increased risk for acute lymphoblastic leukemia
TT: common/normal
rs2024513AA21.7 (1.7)31.24NRXN1AA: 1.7x higher risk for schizophrenia (among Han Chinese)
AG: 1.3x higher risk for schizophrenia (among Han Chinese)
rs7192GT61.7 (3.0)49.28HLA-DRAGG: common/normal
GT: 1.7x increased risk for developing a peanut allergy
TT: 3x higher risk for developing a peanut allergy
rs5400CT
AG
31.7 (1.7)23.29SLC2A2CC: normal sugar consumption
CT: significantly higher sugar consumption?
TT: significantly higher sugar consumption
rs3843763CC201.6 (1.9)53.51PLTPCC: Normal (higher) HDL "Good" Cholesterol.
CT: Slightly lower HDL ("Good") Cholesterol.
TT: Slightly lower HDL ("Good") Cholesterol.
rs2736100GG
CC
51.6 (2.0)26.65TERTGG: 1.6x higher risk for glioma development
GT: 1.3x higher risk for glioma development
TT: higher risk of Interstitial lung disease, and testicular cancer
rs1537415CG91.6 (2.0)46.69GLT6D1CC: normal
CG: 1.6x increased risk for periodontitis
GG: 2x increased risk for periodontitis
rs28694718AG
CT
X1.5 (1.5)44.83CSF2RAAA: >2x higher risk for schizophrenia
AG: 2x higher risk for schizophrenia
GG: common
rs17319721AG41.5 (1.5)46.53SHROOM3AA: reported to have some negative associations with kidney function
AG: reported to have some negative associations with kidney function
GG: Common/Normal
rs17221417CG161.5 (2.0)39.47NOD2CC: normal
CG: 1.3x higher risk for Crohn's disease
GG: 1.9x higher risk for Crohn's disease
rs13149290CC41.5 (1.5)54.85ZNF827CC: Slightly increased risk of developing prostate cancer
CT: Slightly increased risk of developing prostate cancer
TT: Normal risk of developing prostate cancer
rs12593813AG151.5 (2.0)45.84MAP2K5AA: <0.71x risk for restless legs
AG: 0.71x risk for restless legs
GG: normal risk of restless leg syndrome
rs12498742AA41.5 (1.5)54.64SLC2A9AA: 1.25 increased risk for gout
GG: normal reduced risk of gout
rs12037606AG11.5 (2.0)45.61AA: 1.52x risk of developing Crohn's disease
AG: 1.22x risk of developing Crohn's disease
GG: Normal risk of developing Crohn's disease
rs11635424AG151.5 (2.0)45.84MAP2K5AA: <0.70x risk for restless legs
AG: 0.70x risk for restless legs
GG: normal risk of restless leg syndrome
rs11465804GT11.5 (1.5)11.58IL23RGG: 0.68x lower risk for spondylitis
GT: 0.68x lower risk for spondylitis
TT: normal risk
rs11465770CT11.5 (1.5)14.08IL23RCC: normal Crohn's Disease risk
CT: possibly lower risk of Crohn's Disease (OR=0.30)
TT: possibly lower risk of Crohn's Disease (OR=0.30)
rs11171739CT121.5 (2.0)47.12ERBB3CC: 1.75x risk of developing Type-1 diabetes
CT: 1.34x risk of developing Type-1 diabetes
TT: Normal risk of developing Type-1 diabetes
rs11136000TT81.5 (1.5)16.93CLUCC: normal
CT: 0.84x decreased risk for Alzheimer's disease
TT: 0.84x decreased risk for Alzheimer's disease
rs10895068AG
CT
111.5 (1.5)10.08PGRAA: 2.5x increased odds of breast cancer among hormone-using postmenopausal women
AG: 2.5x increased odds of breast cancer among hormone-using postmenopausal women
GG: normal
rs10883365AG101.5 (2.0)47.81LINC01475AA: Normal risk of developing Crohn's disease
AG: 1.2x increased risk for developing Crohn's disease
GG: 1.62x increased risk for developing Crohn's disease
rs10492519AG131.5 (2.0)47.12FAM124AAA: Normal risk of developing prostate cancer
AG: Slightly increased risk of developing prostate cancer
GG: Increased risk of developing prostate cancer
rs9642880GT81.5 (2.0)47.59CASC11GG: Slightly lower risk of Bladder Cancer.
GT: 1.2x increased bladder cancer risk
TT: 1.5x increased bladder cancer risk
rs7774434CT61.5 (2.0)49.47CC: Increased risk of developing primary biliary cirrhosis
CT: Slightly increased risk of developing primary biliary cirrhosis
TT: Normal risk of developing primary biliary cirrhosis
rs7341475GG71.5 (1.5)69.66RELNAA: normal
AG: normal
GG: 1.58x increased schizophrenia risk for women
rs6908425CT61.5 (2.0)33.81CDKAL1CC: 1.95x increased risk of developing Crohn's disease
CT: 1.63x increased risk of developing Crohn's disease
TT: Normal risk of developing Crohn's disease
rs6601764CT101.5 (2.0)47.65CC: 1.52x increased risk of developing Crohn's disease
CT: 1.16x increased risk of developing Crohn's disease
TT: Normal risk of developing Crohn's disease
rs6591536AA111.5 (1.5)45.67OR5A1AA: less able to detect ╬▓-ionone (floral) fragrance
AG: more able to detect ╬▓-ionone (floral) fragrance
GG: more able to detect ╬▓-ionone (floral) fragrance
rs4939883CC181.5 (1.5)67.31CC: associated with higher HDL cholesterol
CT: associated with higher HDL cholesterol
rs4489954GT151.5 (1.8)43.86MAP2K5GG: Normal risk of developing restless legs syndrome
GT: 0.69x risk risk of developing restless legs syndrome
TT: >0.69x risk of developing restless legs syndrome
rs4464148CT181.5 (2.0)38.89SMAD7CC: 1.35x increased risk for colorectal cancer
CT: 1.10x increased risk for colorectal cancer
TT: Normal risk for colorectal cancer
rs4149274CC
GG
91.5 (1.5)46.38ABCA1CC: Associated with higher HDL (good) cholesterol.
CT: associated with higher HDL (good) cholesterol
rs3923809AG61.5 (2.0)43.08BTBD9AA: 1.9x risk for developing restless legs syndrome
AG: Slightly increased risk of developing restless legs syndrome
GG: Normal risk of developing restless legs syndrome
rs3851179AG
CT
111.5 (1.5)45.08AA: 0.85x decreased risk for Alzheimer's disease
AG: 0.85x decreased risk for Alzheimer's disease
GG: normal
rs3825776AG
CT
151.5 (2.0)45.89LIPCAA: Normal risk for ALS
AG: 1.3x increased risk for ALS
GG: >1.3x increased risk for ALS
rs3814570CT101.5 (1.5)36.47TCF7L2CC: Normal risk of developing Crohn's disease
CT: 1.3x increased risk for Crohn's disease with ileal involvement
TT: 1.3x increased risk for Crohn's disease with ileal involvement
rs3784709CT151.5 (1.8)45.02MAP2K5CC: Normal risk of developing restless legs syndrome
CT: 0.71x risk of developing restless legs syndrome
TT: >0.71x risk of developing restless legs syndrome
rs3782179TT121.5 (2.5)61.84KITLGCC: 9x lower odds of testicular cancer
CT: 3x lower odds of testicular cancer risk for men
TT: common, but increased risk of testicular cancer
rs3764880AGX1.5 (1.6)15.62TLR8AA: 1.2 - 1.8x increased tuberculosis risk
AG: possible 1.2 - 1.8x increased tuberculosis susceptibility in females
GG: normal
rs3745516AG191.5 (2.0)36.94SPIBAA: Increased risk of developing primary biliary cirrhosis
AG: Slightly increased risk of developing primary biliary cirrhosis
GG: Normal risk of developing primary biliary cirrhosis
rs3212227AA
TT
51.5 (2.0)61.30IL12BAA: 1.43x increased risk of developing psoriasis and psoriatic arthritis
AC: Significantly increased risk of developing cervical cancer
CC: Significantly increased risk of developing cervical cancer
rs2280714AA
TT
71.5 (1.5)43.48TNPO3AA: 1.4x increased risk of SLE
AG: 1.4x increased risk of SLE
GG: Normal risk of SLE
rs2272127CC21.5 (1.5)68.27IL18RAPCC: Associated with herpes and schizophrenia
CG: Associated with herpes and schizophrenia
rs2007153GG
CC
91.5 (1.5)39.82DBHAA: decreased risk of schizophrenia in limited study
AG: normal risk of schizophrenia in limited study
GG: increased risk of schizophrenia in limited study
rs1994090GT121.5 (2.0)29.64SLC2A13GG: Increased risk of developing Parkinson's Disease
GT: Slightly increased risk of developing Parkinson's Disease
TT: Normal risk of developing Parkinson's Disease
rs1867277AG91.5 (2.0)45.06FOXE1AA: 2x increased risk for thyroid cancer
AG: 1.5x increased risk for thyroid cancer
GG: normal
rs1801274TT
AA
11.5 (1.5)24.98FCGR2ACC: normal risk for cancer progression
CT: complex; generally greater risk for cancer progression
TT: complex; generally greater risk for cancer progression
rs1165205AA
TT
61.5 (1.5)22.82SLC17A3AA: 0.85x decreased gout risk
AT: 0.85x decreased gout risk
TT: normal
rs1063192CT
AG
91.5 (1.5)48.78CDKN2BCC: 0.71x reduced risk of myocardial infarction
CT: 0.71x reduced risk of myocardial infarction
TT: Normal risk of myocardial infarction
rs1042725CC121.5 (1.5)20.74HMGA2CC: ~0.8cm taller
CT: ~0.4cm taller
TT: Average height
rs1026732AG151.5 (2.0)45.58MAP2K5AA: <0.70x risk for restless legs
AG: 0.70x risk for restless legs
GG: normal risk of restless leg syndrome
rs1012053AA131.5 (2.1)70.33DGKHAA: Normal (higher) risk of Bipolar Disorder.
AC: 0.625x reduced risk of Bipolar Disorder.
CC: 0.39x reduced risk of Bipolar Disorder.
rs995030GG121.5 (2.1)63.24KITLGAA: Reduced risk of testicular cancer
GG: non-protective against testicular cancer
rs872071GG61.5 (1.5)22.54IRF4AA: normal risk for chronic lymphocytic leukemia
AG: ~1.5x increased risk for chronic lymphocytic leukemia
GG: ~1.5x increased risk for chronic lymphocytic leukemia
rs763361CT181.5 (2.0)49.34CD226CC: Normal risk for multiple autoimmune diseases
CT: Slightly increased risk for multiple autoimmune diseases, such as type-1 diabetes
TT: Increased risk for multiple autoimmune diseases
rs710521AG
CT
31.5 (2.0)37.63AA: 1.4x increased risk of developing bladder cancer.
AG: Normal risk of developing bladder cancer.
GG: Lower (0.83x) risk of developing bladder cancer.
rs700651AG21.5 (2.0)44.15BOLLAA: Normal risk of aneurysm
AG: ~1.18x increased risk of aneurysm
GG: ~1.56x increased risk of aneurysm
rs501120AA
TT
101.5 (1.5)69.36AA: common, but >1.3x increased risk for heart disease
AG: 1.3x increased risk for heart disease
GG: normal
rs464049CC
GG
51.5 (1.5)20.16SLC6A3CC: decreased risk of schizophrenia in limited study
CT: increased risk of schizophrenia in limited study
TT: increased risk of schizophrenia in limited study
rs420259CT
AG
161.5 (1.9)39.51PALB2CC: Half the risk of developing Bipolar Disorder.
CT: Possibly reduced risk of Bipolar Disorder.
TT: Normal risk of Bipolar Disorder.
rs393152AA171.5 (1.5)61.93C17orf69AA: Increased risk of both PD and AD
AG: Slight increased risk of both PD and AD
GG: Normal risk of both PD and AD
rs309375TT
AA
41.5 (1.5)41.85GG: Smaller mosquito bites
GT: Average mosquito bites
TT: Larger mosquito bites
rs16944AG21.5 (2.0)45.77IL1BAA: Increased risk for osteoarthritis
AG: Minorly increased risk of mental illness and osteoarthritis
GG: Increased risk of mental disorders
rs7041TT
AA
41.5 (1.5)22.10GCTT: ex-smokers at 2x higher risk for COPD; supplement with Vitamin D?
rs5219CT111.5 (2.5)44.85KCNJ11CC: normal
CT: 1.3x increased risk for type-2 diabetes
TT: 2.5x increased risk for type-2 diabetes
rs10516487TT
AA
41.4 (1.4)8.52BANK1CC: common in clinvar
CT: slightly higher risk for lupus
TT: slightly higher risk for lupus
rs7529229TT11.4 (1.4)35.04IL6RCC: 2.5x higher risk of multiple myeloma than AA
TT: 2.5x lower risk for multiple myeloma versus CC
rs6010620GG201.4 (1.4)58.99RTEL1AG: 1.2x higher risk for glioma development
GG: 1.4x higher risk for glioma development; but this is the common allele
rs3131296GG
CC
61.4 (1.4)77.35NOTCH4AA: normal risk for developing schizophrenia
AG: 1.2x increased risk for schizophrenia
GG: 1.4x increased risk for schizophrenia
rs2294008CC81.4 (2.1)30.24PSCACC: lower risk of cancer
TT: increased risk of gastric and bladder cancer
rs1126497CT21.4 (1.4)47.00EPCAMCC: normal
CT: 1.4x increased risk for breast cancer
TT: 1.4x increased risk for breast cancer
rs17465637CC11.3 (1.3)49.19MIA3AC: 1.17x higher risk for myocardial infarction
CC: 1.34x higher risk for myocardial infarction
rs10947262CC61.3 (1.3)79.70BTNL2CC: 1.3x increased risk for osteoarthritis
rs10050860CC51.3 (1.7)64.68ERAP1CC: Normal risk (about 0.1%) for Ankylosing Spondylitis.
CT: 0.71x lower risk for Ankylosing Spondylitis.
TT: Half the risk (about 0.05%) of Ankylosing Spondylitis.
rs4958847AG51.3 (2.6)24.11IRGMAA: 2.6x increased risk for Crohn's disease
AG: 1.3x increased risk for Crohn's disease
GG: normal
rs2549782GT51.3 (1.6)53.61ERAP2GG: 1.6x increased risk for preeclampsia in most populations
GT: 1.3x increased risk for preeclampsia in most populations
rs1421085CT161.3 (1.7)44.99FTOCC: ~1.7x increased obesity risk
CT: ~1.3x increased obesity risk
TT: normal obesity risk
rs1260326CT21.3 (1.6)46.90GCKRCT: slightly higher risk for gout
TT: slightly higher risk for gout
rs356219AG41.3 (1.6)46.43SNCAAA: normal
AG: 1.3x increased risk for Parkinson's disease
GG: 1.6x increased risk for Parkinson's disease
rs110419AG111.3 (2.6)49.77LMO1AA: 2.6x increased risk for neuroblastoma
AG: 1.3x increased risk for neuroblastoma
rs11246226AC111.2 (1.2)51.34DRD4AA: increased risk of schizophrenia in limited study
AC: decreased risk of schizophrenia in limited study
CC: decreased risk of schizophrenia in limited study
rs10513789TT31.2 (2.0)61.05MCCC1GG: lower risk of Parkinson's disease
GT: increased risk of Parkinson's disease
TT: Very common. Normal risk of Parkinson's disease.
rs9858542AG31.2 (1.3)40.60BSNAA: 1.8x risk
AG: 1.1x risk Crohn's Disease
GG: normal
rs8050136AC161.2 (1.4)45.34FTOAA: 1.4x increased risk for T2D in some populations
AC: 1.2x increased risk for T2D in some populations
CC: normal
rs6625163AAX1.2 (1.2)26.25AA: increased risk of baldness
AG: None
GG: None
rs6036025GG201.2 (1.2)83.22C19orf26GG: more likely to go bald
rs4977756AG91.2 (1.4)49.03CDKN2BASAG: 1.2x higher risk for glioma development
GG: 1.4x higher risk for glioma development
rs4795067AG171.2 (1.4)43.96NOS2AA: normal/common in clinvar
AG: slight increase in risk for psoriatic arthritis
GG: slight increase in risk for psoriatic arthritis
rs4324715CC51.2 (1.2)26.44CC: >1.5x increased testicular cancer risk for men
CT: 1.5x increased testicular cancer risk for men
TT: Normal risk of testicular cancer.
rs3802842AC111.2 (2.0)39.70C11orf93AA: normal
AC: 1.17x increased risk of colorectal cancer
CC: >1.17x increased risk of colorectal cancer
rs3129878AC61.2 (1.3)41.00HLA-DRAAC: slightly higher risk for infertility in Chinese men
CC: slightly higher risk for infertility in Chinese men
rs2252586AG
CT
71.2 (1.4)39.89AA: 1.4x higher risk for glioma development
AG: 1.2x higher risk for glioma development
rs2223841AA
TT
X1.2 (2.0)26.42AA: more likely to go bald before age 40
GG: less likely to go bald
rs2076295GT61.2 (1.5)47.90DSPGG: Slightly increased risk for pulmonary fibrosis (and decreased DSP expression)
GT: One copy of the risk allele (G), slightly increased risk for pulmonary fibrosis
TT: common/normal (higher levels of DSP expression)
rs2070074AG91.2 (1.5)18.91GALTAA: common in clinvar
AG: harmless ancestral galactosemia variant carrier
rs1805388CT
AG
131.2 (2.0)24.86LIG4AA: reduced risk of multiple myeloma
CC: common in clinvar
CT: 1.5x reduced risk of multiple myeloma
rs1344706TT
AA
21.2 (1.2)40.17ZNF804AGG: normal
GT: 1.1x increased risk for schizophrenia
TT: 1.2x increased risk for schizophrenia
rs909525AA
TT
X1.2 (2.0)18.43MAOAAA: Probably MAOA 4 or 5 repeats: not Warrior Gene.
AG: Probably one Warrior Gene and one non-Warrior Gene.
GG: Perhaps MAOA 3 repeats: Warrior Gene?
rs610932AC
GT
111.2 (1.5)49.30MS4A6AAA: A allele associated with reduced risk of Alzheimer's in Chinese Han population.
rs30187CC51.2 (2.0)39.82ERAP1CC: Normal low risk (0.1%) for ankylosing spondylitis.
CT: 1.4x higher risk for Ankylosing Spondylitis.
TT: 2x higher risk for Ankylosing Spondylitis.
rs34516635GG151.1 (1.5)99.41IGF1RAA: Possibly increased longevity for Ashkenazi Jewish women.
AG: Possibly increased longevity for Ashkenazi Jewish women.
GG: Less longevity for Ashkenazi Jewish women.
rs16891982GG51.1 (2.0)79.82SLC45A2CC: generally non-European, but if European, 7x more likely to have black hair
CG: if European, 7x more likely to have black hair
GG: Generally European; Light skin; Possibly an increased risk of melanoma
rs11650354CC171.1 (2.0)70.13TBX21CC: 8x risk for allergic asthma; common
CT: possible risk for allergic asthma
rs11110912CC121.1 (1.1)66.60MYBPC1CC: 1.3x high blood pressure risk
CG: 1.3x high blood pressure risk
GG: normal
rs11037909CT111.1 (1.2)39.01EXT2CT: 1.27x type II diabetes risk
TT: 1.47x type II diabetes risk
rs10495584AA21.1 (2.5)94.81LPIN1AA: Normal (higher) blood pressure.
AG: Lowers men's blood pressure by -6.3/-3.8 mm Hg.
GG: Lowers men's blood pressure by -6.3/-3.8 mm Hg.
rs10166942CT21.1 (1.3)31.64TRPM8CC: 0.7x lower risk for migraines
CT: 0.85x lower risk for migraines
TT: common in complete genomics
rs7794745AA71.1 (2.0)41.29CNTNAP2AA: normal risk (for autism)
AT: slightly increased risk for autism
TT: slightly increased risk for autism
rs7568369GT21.1 (1.1)47.24KLF7GG: normal
GT: 0.90x reduced risk of obesity
TT: 0.90x reduced risk of obesity
rs7171755AA151.1 (1.1)17.86C15orf60AA: very slight descrease in cortical thickness and IQ; see full description
AG: very slight decrease in cortical thickness and IQ; see full text
GG: common/normal
rs4988235TT
AA
21.1 (2.5)31.08MCM6CC: likely to be lactose intolerant as an adult
CT: likely to be able to digest milk as an adult
TT: can digest milk
rs4794067TT171.1 (2.0)55.95TBX21CC: 2.1x risk for Aspirin Induced Asthma. But possibly lower risk of lupus and intractable Graves' disease.
CT: 2.1x risk for Aspirin Induced Asthma. But possibly lower risk of intractible Grave's disease.
TT: Lower risk of Aspirin Induced Asthma. Normal (higher) risk of lupus and intractable Grave's Disease.
rs3758549CC
GG
101.1 (1.1)67.08GBF1CC: increased risk of parkinson's disease
CT: normal risk of parkinson's disease
TT: normal risk of parkinson's disease
rs3740878AG
CT
111.1 (1.2)38.95EXT2AA: 1.46x type II diabetes risk; common
AG: 1.26x type II diabetes risk
rs2828520GG211.1 (1.1)11.40AG: Higher major depressive disorder risk ?
GG: 1.35x major depressive disorder risk
rs2653349GG61.1 (1.1)67.50HCRTR2AA: normal
AG: ~1.5x? increased risk for cluster headaches
GG: 2-6x increased risk for cluster headaches
rs2291834CC11.1 (1.1)48.86MIA3CC: very slightly higher risk for myocardial infarction
CT: very slightly higher risk for myocardial infarction
TT: normal
rs1892534AG
CT
11.1 (1.5)46.52AA: Lower C-Reactive Protein levels. 1.2x increased risk overall for cancers.
AG: Normal C-Reactive Protein levels. Very slight (x1.05) increase in overall risk for cancers.
GG: Slightly higher C-Reactive Protein levels. Possibly slightly lower cancer risk.
rs1229984GG
CC
41.1 (2.0)87.70ADH1BAA: 0.56x decreased risk of oral/throat cancers
AG: 0.56x decreased risk of oral/throat cancers
GG: normal oral/throat cancer risk; more frequent alcohol consumption
rs925391CC
GG
X1.1 (3.0)27.80CC: more likely to go bald; common
CT: lower odds of going bald
TT: unlikely to go bald
rs889312CC51.1 (1.1)8.53AA: normal
AC: Very slightly higher risk for breast cancer
CC: Very slightly higher risk for breast cancer
rs838133TT
AA
191.1 (1.1)17.41FUT1CC: Lower odds preferring sweet snack
CT: Typical odds preferring sweet snack
TT: Higher odds preferring sweet snack
rs713598CG71.1 (1.1)49.12TAS2R38CC: Can taste bitter.
CG: Can taste bitter.
GG: Possibly unable to taste bitter in some foods.
rs363050AG201.1 (1.1)47.99SNAP25
rs249954CT
AG
161.1 (1.2)36.73PALB2CC: common in clinvar
CT: slight if any increased risk of Breast Cancer
TT: either no, or slightly increased risk, of Breast Cancer
rs31489AA51.1 (2.0)15.59CLPTM1LAA: Reduced lung cancer risk?
AC: 1.75-fold reduced risk of developing lung cancer
CC: Increased risk for lung cancer and emphysema
rs7412CC191.1 (1.1)85.95APOECC: more likely to gain weight if taking olanzapine
CT: more likely to gain weight if taking olanzapine
TT: normal
rs4880CT
AG
61.1 (1.1)49.84SOD2CC: complex! see rs4880
CT: complex! see rs4880
TT: complex! see rs4880
rs16953002GG161.0 (1.5)68.38FTOAA: 1.32x increased risk of melanoma in those with low BMI
AG: 1.16x increased risk of melanoma in indiiduals with low BMI
GG: Slightly lower risk of melanoma in individuals with low BMI
rs13333226AA161.0 (1.2)67.00UMODAA: common but slightly higher risk for hypertension
AG: slightly lower risk for hypertension
GG: ~15-20% lower risk for hypertension or cardiovascular events
rs12934922AT161.0 (1.0)48.18BCMO1AA: normal
AT: Reduced conversion of beta-carotene to retinol
TT: Reduced conversion of beta-carotene to retinol
rs12752888CT11.0 (1.0)41.25CC: Faster progression of mild cognitive impairment to AlzheimerÔÇÖs disease.
CT: Normal progression to AlzheimerÔÇÖs disease from mild cognitive impairment.
TT: Normal progression to AlzheimerÔÇÖs disease from mild cognitive impairment.
rs12571093AG101.0 (1.0)26.74LOC100128041AA: ancestral Neanderthal allele (homozygote)
AG: ancestral Neanderthal allele (heterozygote)
GG: common on affy axiom data
rs12003612CC91.0 (1.0)81.60PLAA
rs11974297GG71.0 (1.0)99.80DDCGG: Migraine
rs10757272CC91.0 (2.0)27.32CDKN2B-AS1CC: Normal risk for Coronary artery disease
CT: 1.30x increased risk for Coronary artery disease
TT: 1.54x increased risk for Coronary artery disease
rs10504861GG
CC
81.0 (2.0)64.95AA: Reduced risk of migraine without aura
AG: Reduced risk of migraine without aura
GG: Major allele, normal risk of migraine
rs10501570TT111.0 (1.0)68.21DLG2TT: Normal risk of developing Parkinson's Disease
rs10488631TT71.0 (3.0)82.15TNPO3CC: 2x increased risk of developing SLE; 3.2x increased risk of developing primary biliary cirrhosis; and 3.4x increased risk of developing Sj÷gren's syndrome
CT: 2x increased risk of developing SLE; 1.6x increased risk of developing primary biliary cirrhosis; and 1.7x increased risk of developing Sj÷gren's syndrome
TT: Normal risk of developing SLE, primary biliary cirrhosis, and Sj÷gren's syndrome
rs10260404TT71.0 (2.0)40.51DPP6CC: 1.60x risk of developing ALS
CT: 1.20x risk of developing ALS
TT: Normal risk of developing ALS
rs9357271TT61.0 (1.0)53.35BTBD9CC: <0.63x risk for restless legs
CT: 0.63x risk for restless legs
TT: Normal risk of developing restless legs syndrome
rs7910977CT101.0 (1.0)24.05IDECC: common in complete genomics
CT: ~0.80x (lower) risk for late onset Alzheimer's disease
TT: ~0.80x (lower) risk for late onset Alzheimer's disease
rs7850258AG91.0 (1.5)42.89AA: Slightly lower odds of developing primary hypothyroidism.
AG: Typical odds of developing primary hypothyroidism.
GG: Slightly higher odds of developing primary hypothyroidism.
rs6932590CT61.0 (1.0)34.77TRNAV27CC: rare but normal
CT: 1.1x increased risk for schizophrenia
TT: 1.1x increased risk for schizophrenia
rs6812193CT41.0 (1.5)44.71FAM47ECC: slightly higher risk of developing Parkinson's Disease for caucasians
CT: normal risk of developing Parkinson's Disease
TT: Slightly decreased risk of developing Parkinson's Disease
rs6603272TTY1.0 (2.0)55.55IL3RAGG: >2.74x increased risk of developing schizophrenia
GT: 2.74x increased risk of developing schizophrenia
TT: Normal risk of developing schizophrenia
rs6583817CT101.0 (1.0)24.33IDECC: common in complete genomics
CT: ~0.80x (lower) risk for late onset Alzheimer's disease
TT: ~0.80x (lower) risk for late onset Alzheimer's disease
rs6532197AA41.0 (2.0)82.61AA: Normal risk of developing Parkinson's Disease
AG: Slightly increased risk of developing Parkinson's Disease
GG: Increased risk of developing Parkinson's Disease
rs4979462CC91.0 (2.0)94.28TNFSF15CC: Normal risk of developing primary biliary cirrhosis
CT: Slightly increased risk of developing primary biliary cirrhosis
TT: Increased risk of developing primary biliary cirrhosis
rs4939827CT181.0 (1.5)48.78SMAD7CC: 0.73x decreased risk for colorectal cancer
CT: 0.86x decreased risk for colorectal cancer
TT: 1x risk for colorectal cancer
rs4792311GG171.0 (2.0)49.84ELAC2AA: Increased risk of prostate cancer
AG: Increased risk of prostate cancer
GG: Normal risk of prostate cancer
rs4778138AA151.0 (1.0)66.08OCA2AA: freckles more likely
rs4626664GG91.0 (2.0)69.68PTPRDAA: >1.44x increased risk of developing restless legs syndrome
AG: 1.44x increased risk of developing restless legs syndrome
GG: Normal risk of developing restless legs syndrome
rs4538475AA41.0 (2.0)67.00BST1AA: Normal risk of developing Parkinson's Disease
AG: Slightly increased risk of developing Parkinson's Disease
GG: Increased risk of developing Parkinson's Disease
rs4273077AA171.0 (2.0)75.80TNFRSF13BAA: Normal risk for development of MGUS
AG: Possibly slight 1.09x risk for development of MGUS
GG: 3.57x increased risk of MGUS
rs3087243GG21.0 (1.5)31.31CTLA4AA: increased risk for auto-immune diseases
AG: increased risk for auto-immune diseases
GG: Normal risk for autoimmune diseases
rs2952768CT21.0 (1.0)44.98CC: less drug dependence, decreased effectiveness of analgesics
CT: slightly less drug dependence, decreased effectiveness of analgesics
TT: normal/slightly increased risk of drug dependence, normal effectiveness of analgesics
rs2881766GG61.0 (1.5)5.51ESR1GG: Normal risk for pregnancy-induced hypertension
GT: Slightly increased risk for pregnancy-induced hypertension
TT: Slightly increased risk for pregnancy-induced hypertension
rs2854747CT
AG
71.0 (1.0)48.41IGFBP3CC: 2326.08ng/mL of IGFBP-3 in plasma
CT: 2659.70ng/mL of IGFBP-3 in plasma
TT: 2743.02ng/mL of IGFBP-3 in plasma
rs2814778AA
TT
11.0 (1.0)96.12DARCAA: Duffy-positive
AG: Duffy-positive
GG: Duffy-negative: increased odds of HIV infection upon exposure, but slowed disease progression if infected
rs2697962GG
CC
11.0 (2.0)71.07PRDM2AA: Increased risk of developing Parkinson's Disease
AG: Slightly increased risk of developing Parkinson's Disease
GG: Normal risk of developing Parkinson's Disease
rs2351299GG41.0 (1.0)68.82GABRB1GG: normal risk of autism
GT: possible reduced risk of Autism
TT: possible reduced risk of autism
rs2302009GT
AC
71.0 (1.2)37.13CCL26GG: 4.6x risk of eosinophilic esophagitis
GT: normal
TT: normal
rs2283123CC91.0 (1.0)78.52DBHCC: normal risk of schizophrenia in limited study
CT: decreased risk of schizophrenia in limited study
TT: decreased risk of schizophrenia in limited study
rs2273697AG101.0 (1.0)32.46ABCC2AA: Adverse reaction more likely to carbamazepine in epileptic patients
AG: Adverse reaction more likely to carbamazepine in epileptic patients
GG: normal/common
rs2060793GG111.0 (2.0)37.32CYP2R1AA: Lower serum levels of vitamin D
GG: Higher serum levels of vitamin D
rs1975197CC
GG
91.0 (2.0)68.88PTPRDCC: Normal risk of developing restless legs syndrome
CT: 1.3x increased risk of developing restless legs syndrome
TT: >1.3x increased risk of developing restless legs syndrome
rs1861046GG41.0 (1.0)89.79C1QTNF7
rs1835740AG
CT
81.0 (1.0)37.08LOC101927066AA: higher risk for migraine in 1 study which has not replicated
AG: unreplicated, higher risk for migraine
GG: normal
rs1800469CC
GG
191.0 (1.0)45.34TGFB1CC: lower TGF-╬▓1 levels, higher risk for COPD?
CT: slightly higher TGF-╬▓1 levels, higher risk for COPD?
TT: higher TGF-╬▓1 levels
rs1800407GG
CC
151.0 (1.0)88.41OCA2AA: green/hazel/brown/black eyes more likely
AG: green/hazel/brown/black eyes more likely
GG: blue/gray eyes more possible
rs1800401CC
GG
151.0 (1.0)87.23OCA2CC: blue/gray eyes possible
CT: brown/black eyes more likely
TT: brown/black eyes more likely
rs1800255AG21.0 (2.5)37.52COL3A1AA: increased risk for pelvic organ prolapse
AG: benign
GG: normal
rs1601012CC121.0 (1.0)64.05SCN8AAA: possible decreased suicide risk
CC: normal suicide risk
rs1223271GG201.0 (2.0)71.47AA: Increased risk of developing Parkinson's Disease
AG: Slightly increased risk of developing Parkinson's Disease
GG: Normal risk of developing Parkinson's Disease
rs1143674AG21.0 (1.0)46.41ITGA4AA: 1.3x increased autism risk
AG: 1.3x increased autism risk
GG: normal (risk of Autism)
rs1061147AC11.0 (2.0)44.24CFHAA: 2.76x increased risk for Age Related Macular Degeneration.
AC: Normal 0.97x risk for Age Related Macular Degeneration.
CC: Reduced 0.34x risk of Age Related Macular Degeneration.
rs1052576GG
CC
11.0 (1.7)23.33CASP9AA: 0.5x reduced risk of multiple myeloma, general reduced risk of cancer
AG: 0.8x reduced risk of multiple myeloma, general reduced risk of cancer
GG: Increased risk of multiple myeloma, B-cell neoplasms, and cancer in general
rs926103AA
TT
11.0 (1.0)13.52SH2D2AAA: Possible increased risk of multiple sclerosis if SH2D2A promoter GA repeat=16
AG: No increased risk.
GG: No increased risk.
rs729302AA71.0 (1.5)46.46AA: Normal risk of developing rheumatoid arthritis
AC: 0.89x decreased risk of developing rheumatoid arthritis
CC: 0.89x decreased risk of developing rheumatoid arthritis
rs642961GG11.0 (2.0)63.66AA: 2.40x increased risk of cleft lip
AG: 1.68x increased risk of cleft lip
GG: Normal risk of cleft lip
rs492602CT
AG
191.0 (1.5)49.97FUT2CC: Higher B12 levels in women
CT: Normal B12 levels
TT: Normal B12 levels
rs486907GG
CC
11.0 (2.0)43.39RNASELAA: 2x increased prostate cancer risk
AG: 1.5x increased prostate cancer risk
GG: Normal prostate cancer risk
rs199533CC
GG
171.0 (2.0)66.37NSFCC: Normal risk of developing Parkinson's Disease
CT: Slightly increased risk of developing Parkinson's Disease
TT: Increased risk of developing Parkinson's Disease
rs187116CT
AG
111.0 (1.0)51.91CD44CC: among patients with gastric cancer, risk for more aggressive form?
CT: among patients with gastric cancer, risk for more aggressive form?
rs182549TT21.0 (2.0)31.95MCM6CC: possibly lactose intolerant
CT: Can digest milk.
TT: Can digest milk.
rs167771AA31.0 (1.1)65.44DRD3
rs165599AG221.0 (1.5)44.71COMTGG: May indicate increased susceptibility to schizophrenia
rs140701GG
CC
171.0 (1.5)31.83SLC6A4AA: Increased risk for anxiety disorders
AG: Increased risk for anxiety disorders
GG: Normal risk for anxiety disorders
rs13181TT191.0 (2.0)38.95ERCC2GG: >1.12x increased risk for cutaneous melanoma
GT: 1.12x increased risk for cutaneous melanoma
TT: Normal risk for cutaneous melanoma
rs11362AG
CT
81.0 (1.0)49.25DEFB1
rs1048661GT150.5 (1.0)48.86LOXL1GG: possibly higher glaucoma risk?
GT: possibly higher glaucoma risk?
TT: average
rs736839CT180.5 (0.5)42.70SMAD7CC: common, increased risk for sickle cell leg ulcers
CT: lower risk
TT: lower risk
rs237025TT
AA
60.5 (0.5)28.90SUMO4CC: common in clinvar
TT: no credible risk
rs28937899CC
GG
190.3 (3.0)99.93CC: common in clinvar
rs12416000GG100.1 (2.0)80.46AA: Neanderthal gene
AG: mixed homo-sapiens (human) and Neanderthal
GG: homo sapiens gene (not Neanderthal)
rs10513025TT50.1 (2.1)92.79CC: >0.55x reduced risk for autism
CT: 0.55x reduced risk for autism
TT: normal risk of Autism
rs10246939CT70.1 (1.1)50.03TAS2R38CC: can taste bitter
CT: can taste bitter
TT: possibly unable to taste bitterness
i4001473AG0.1 (0.1)87.98AG: common
rs1801282CC30.1 (3.0)78.58PPARGCC: normal fat metabolism; common in clinvar
CG: watch out for high fat in diet
GG: watch out for high fat in diet
rs1800629GG60.1 (2.5)72.51TNFAA: complex; generally higher risk for certain diseases
AG: complex; generally higher risk for certain diseases
GG: complex; generally normal risk
rs1799853CC100.1 (2.1)78.15CYP2C9CC: normal; no change in warfarin metabolism
CT: CYP2C9*2 carrier; average 20% reduction in warfarin metabolism
TT: CYP2C9*2 homozygote; average 40% reduction in warfarin metabolism
rs1726866CT
AG
70.1 (1.1)50.03TAS2R38CC: can taste bitter
CT: can taste bitter
TT: possible unable to taste bitter
rs1080983AG
CT
220.1 (0.1)40.01CYP2D6AG: common
rs1061235AA60.1 (4.0)90.37HLA-AAA: Normal carbamazepine sensitivity; common in clinvar
AT: 26% risk of bad reaction to anti-epileptic carbamazepine
TT: 26% risk of bad reaction to anti-epileptic carbamazepine
rs1057910AA100.1 (4.0)88.51CYP2C9AA: normal; no effect on warfarin metabolism
AC: CYP2C9*3 carrier; average 40% reduction in warfarin metabolism
CC: CYP2C9*3 homozygote; average 80% reduction in warfarin metabolism; reduced metabolism of number of other drugs
rs1018381CC
GG
60.1 (2.0)82.52DTNBP1CC: normal cognitive ability
TT: impaired cognitive ability
rs601338AG190.1 (2.5)50.16FUT2AA: resistance to Norovirus infection
AG: susceptible to Norovirus infections
GG: susceptible to Norovirus infections
rs16947AG220.1 (0.1)47.65CYP2D6AA: Homozygous for CYP2D6 variants (non-CYP2D6*1)
AG: a common variant
GG: normal
rs200563280CC190.0 (4.0)99.87RYR1CC: common
CT: malignant hyperthermia
rs138326449GG110.0 (4.0)98.99APOC3AG: rare variant with large positive effect
GG: common in ClinVar
rs121965064TT40.0 (5.0)99.74F11CC: Factor XI deficiency
CT: carrier of factor XI mutation
TT: common in clinvar
rs121965063GG40.0 (5.0)99.87F11GG: common in clinvar
GT: carrier of factor XI mutation
TT: Factor XI deficiency
rs121434369CC190.0 (7.0)99.74GCDHCC: common in clinvar
CT: Unaffected carrier of a glutaric acidemia type I mutation
TT: glutaric acidemia type I
rs121434282GG10.0 (5.0)99.74ACADMCC: Medium-Chain Acyl-CoA Dehydrogenase Deficiency
CG: Carrier of Medium-Chain Acyl-CoA Dehydrogenase Deficiency
GG: common in clinvar
rs121434280TT10.0 (5.0)99.74ACADMCC: Medium-Chain Acyl-CoA Dehydrogenase Deficiency
CT: Carrier of Medium-Chain Acyl-CoA Dehydrogenase Deficiency
TT: common in clinvar
rs111033171TT
AA
90.0 (3.0)99.87IKBKAPCT: carrier of familial dysautonomia mutation
TT: common in clinvar
rs104895097GG
CC
160.0 (5.0)99.87MEFVAA: familial mediterranean fever
AG: carrier for familial mediterranean fever
GG: common in clinvar
rs104895083GG16 (3.0)99.87MEFVCC: common in clinvar
CG: carrier of familial mediterranean fever allele
rs104886456AA
TT
90.0 (5.0)99.87FANCCAA: common in complete genomics
AT: Fanconi anemia carrier
TT: Fanconi Anemia (FANCC-related)
rs79874540CC
GG
20.0 (3.0)99.87HTR2BCC: common in complete genomics
rs78655421GG70.0 (3.0)99.74CFTRAG: Cystic fibrosis allele (carrier)
GG: common in clinvar
rs78378222AA
TT
170.0 (3.0)98.81TP53AA: normal
AC: cancer risk
CC: cancer risk
rs77931234TT
AA
10.0 (5.0)99.60ACADMCC: Medium-Chain Acyl-CoA Dehydrogenase Deficiency
CT: Carrier of Medium-Chain Acyl-CoA Dehydrogenase Deficiency
TT: common in clinvar
rs77834169CC70.0 (3.0)99.87CFTRCC: common in clinvar
CT: Unaffected carrier of cystic fibrosis variant
rs77409459CC70.0 (3.0)99.60CFTRCC: common in clinvar
CT: cystic fibrosis carrier
rs76917243GG90.0 (5.0)99.87ALDOBGG: common in clinvar
GT: carrier for hereditary fructose intolerance allele
TT: hereditary fructose intolerance
rs76713772GG70.0 (3.0)99.87CFTRAG: Cystic Fibrosis carrier
CC: common in complete genomics
GG: common in clinvar
rs76173977CC150.0 (5.0)99.87HEXACC: common in clinvar
CT: Tay-Sachs disease carrier
TT: Tay-Sachs disease
rs75932628CC60.0 (3.5)99.60TREM2CT: risk of Alzheimer's disease
TT: risk of Alzheimer's disease
rs75193786TT
AA
120.0 (6.0)99.87PAHCC: Phenyketonuria
CT: carrier of Phenylketonuria allele
TT: common in clinvar
rs75039782CC70.0 (3.0)99.74CFTRCC: common in clinvar
CT: Cystic fibrosis allele (carrier)
GG: common in complete genomics
rs67376798TT10.0 (3.5)99.09DPYDAA: 5-fluorouracil toxicity
AT: carrier of a null DPYD allele
TT: common/normal
rs63750451CC
GG
70.0 (5.0)99.94PMS2CC: common in clinvar
CT: hereditary nonpolyposis colorectal cancer (HNPCC4)
TT: hereditary nonpolyposis colorectal cancer (HNPCC4)
rs63750197CC10.0 (7.0)99.79PSEN2CC: common in clinvar
CT: possible early-onset Alzheimer's disease but causation unclear; dilated cardiomyopathy
rs62642933TT
AA
120.0 (6.0)99.75PAHGG: Phenyketonuria
GT: carrier of Phenylketonuria allele
TT: common in clinvar
rs61757781AA10.0 (1.5)99.81PSEN2AA: Normal
AG: Carrier of possibly damaging mutation leading to Alzheimer's Disease
GG: Carrier of possibly damaging mutation leading to Alzheimer's Disease
rs61753344GG10.0 (3.0)99.74FMO3GG: common in clinvar
GT: trimethylaminuria, to varying degrees
TT: trimethylaminuria & possible related issues
rs61751362CC
GG
X0.0 (2.5)40.56MECP2CC: common in clinvar
CT: increased risk of Rett syndrome and Autism
TT: increased risk of Rett syndrome and Autism
rs61750420GG
CC
70.0 (5.0)99.68PEX1AA: peroxisomal biogenesis disorder (Zellweger) allele
AG: carrier of peroxisomal biogenesis disorder (Zellweger) allele
GG: common in clinvar
rs61732874CC160.0 (5.0)99.75MEFVAA: familial mediterranean fever
AC: carrier for familial mediterranean fever
CC: common in clinvar
rs59912467CC190.0 (2.5)98.96STK11CC: common in clinvar
CG: somewhat possible association with Peutz-Jeghers syndrome
rs56244447AA70.0 (3.0)99.94CYP3A5AA: normal
AC: carrier of one CYP3A5*3D allele
CC: CYP3A5*3D homozygote; nonexpressor for CYP3A5
rs55960271CC70.0 (6.0)99.48CLCN1CC: common in clinvar
CT: Myotonia congenita; quite variable in degree
TT: Myotonia congenita; quite variable in degree
rs55886062AA10.0 (3.5)99.94DPYDAA: common/normal
AC: carrier of a null DPYD allele
CC: 5-fluorouracil toxicity
rs45620037CC
GG
30.0 (4.0)99.87SCN5ACC: common in clinvar
CT: increased risk for dilated cardiomyopathy
TT: increased risk for dilated cardiomyopathy
rs41309764CC
GG
90.0 (5.0)99.87NOTCH1CC: normal
CT: Congenital heart disease and valve calcification likely
TT: Congenital heart disease and valve calcification
rs41298442AA
TT
140.0 (4.0)99.94GCH1AA: common in clinvar
GG: dystonia due to autosomal recessive GCH1 mutation
rs41291556TT100.0 (3.0)99.75CYP2C19CC: CYP2C19*8 homozygote
CT: carrier of one CYP2C19*8 allele, considered a "slow metabolizer"
TT: normal
rs41279857GG70.0 (3.0)99.44CYP3A5GG: normal
GT: carrier of one CYP3A5*S100Y allele
TT: CYP3A5*S100Y homozygote; nonexpressor for CYP3A5
rs41261344CC30.0 (4.0)99.62SCN5ACC: common in clinvar
CT: possible susceptibility to long QT syndrome
TT: possible susceptibility to long QT syndrome
rs36212066II110.0 (4.0)99.81MYBPC3DD: Hypertrophic Cardiomyopathy
DI: Hypertrophic Cardiomyopathy carrier
rs36053993GG
CC
10.0 (2.0)98.93MUTYHAA: increased risk for certain cancers?
AG: increased risk for certain cancers?
GG: common in clinvar
rs35753505TT80.0 (2.0)42.80
rs35264875AA110.0 (3.0)72.42TPCN2AA: common in clinvar
TT: blonde hair color
rs34637584GG120.0 (3.0)99.75LRRK2AA: 15 to 30% chance of Parkinson's disease, depending on age, family history, and ethnicity
AG: 15 to 30% chance of Parkinson's disease, depending on age, family history, and ethnicity
GG: normal
rs34612342AA
TT
10.0 (2.0)99.67MUTYHAA: common in clinvar
AG: increased risk for certain cancers?
GG: increased risk for certain cancers?
rs33980500CC60.0 (2.0)85.90TRAF3IP2CC: common on affy axiom data
CT: 1.6x increase in risk for psoriatic arthritis
TT: 1.6x increase in risk for psoriatic arthritis
rs28997576GG
CC
20.0 (2.5)96.56BARD1CC: probably increased risk of breast cancer
CG: increased risk for breast cancer, at least in predisposed families
GG: common in complete genomics
rs28940579TT
AA
160.0 (3.5)99.50MEFVCC: familial Mediterranean fever
CT: familial Mediterranean fever carrier
TT: common in clinvar
rs28939383CC
GG
60.0 (6.0)99.94CT: carrier of a polycystic kidney disease allele
TT: Polycystic kidney disease
rs28937900CC190.0 (5.0)99.72AA: Limb-girdle muscular dystrophy-dystroglycanopathy
AC: carrier for Limb-girdle muscular dystrophy-dystroglycanopathy
CC: common in clinvar
rs28937869CC50.0 (4.0)99.94CC: common in clinvar
CT: carrier for Ehlers-Danlos syndrome
TT: Ehlers-Danlos syndrome
rs28937289GG
CC
X0.0 (3.0)39.84F8GG: common in clinvar
rs28937287TT
AA
X0.0 (3.0)39.87F8TT: common in clinvar
rs28937285GG
CC
X0.0 (3.0)39.81F8GG: common in clinvar
rs28937282CC
GG
X0.0 (3.0)39.85F8CC: common in clinvar
rs28937272AA
TT
X0.0 (3.0)39.82F8AA: common in clinvar
rs28936679GG170.0 (2.0)99.34AANATAG: in Japanese, possible delayed sleep phase condition
GG: common in complete genomics
rs28936415GG160.0 (4.0)99.57PMM2AG: carrier of Congenital Disorder of Glycosylation Type 1a allele
GG: common in clinvar
rs28935474CC
GG
X0.0 (2.0)41.10CC: normal
rs28933693CC170.0 (5.0)99.94SGCACC: common in clinvar
CT: carrier for Limb-girdle muscular dystrophy-dystroglycanopathy
TT: Limb-girdle muscular dystrophy-dystroglycanopathy
rs28933681GG
CC
X0.0 (3.0)39.82F8GG: common in clinvar
rs28933679AA
TT
X0.0 (3.0)39.85F8AA: common in clinvar
rs28933676AA
TT
X0.0 (3.0)39.87F8AA: common in clinvar
rs28933675CC
GG
X0.0 (3.0)39.92F8CC: common in clinvar
rs28933673GG
CC
X0.0 (3.0)39.81F8GG: common in clinvar
rs28933671AA
TT
X0.0 (3.0)39.90F8AA: common in clinvar
rs28933670TT
AA
X0.0 (3.0)39.82F8TT: common in clinvar
rs28933669TT
AA
X0.0 (3.0)39.85F8TT: common in clinvar
rs28933668CC
GG
X0.0 (3.0)41.30F8CC: common in clinvar
rs28933390GG
CC
30.0 (4.0)98.87BCHEGG: common in clinvar
GT: Pseudocholinesterase Deficiency carrier
TT: Pseudocholinesterase Deficiency
rs28933389CC
GG
30.0 (3.5)99.87BCHECC: common in clinvar
CT: Pseudocholinesterase Deficiency carrier
TT: Pseudocholinesterase Deficiency
rs28933375AA
TT
100.0 (5.0)98.68PRF1AA: common in clinvar
AG: Missense mutation in PRF1 gene, probably recessive
GG: Familial Hemophagocytic Lymphohistiocytosis and Lymphoma
rs28931573CC
GG
110.0 (3.0)99.81CC: common in clinvar
CT: positive for the APOA1 Milano variant
TT: homozygous for the APOA1 Milano variant
rs28929474GG
CC
140.0 (4.0)96.99SERPINA1AA: Alpha-1 Antitrypsin Deficiency
AG: carrier for Alpha-1 Antitrypsin Deficiency
GG: common in complete genomics
rs28399504AA100.0 (2.5)99.56CYP2C19AA: normal
AG: carrier of a CYP2C19*4 allele, considered a "slow metabolizer" variant
GG: poor metabolizer
rs28399424CC150.0 (2.0)99.56CYP1A2CC: normal
CT: carrier of one CYP1A2*6 allele
TT: CYP1A2*6 homozygote
rs28371685CC100.0 (2.5)99.69CYP2C9CC: normal
CT: carrier of one CYP2C9*11 allele
TT: CYP2C9*11 homozygote
rs28365083CC
GG
70.0 (3.0)99.31CYP3A5AA: CYP3A5*2 homozygote; nonexpressor for CYP3A5
AC: carrier of one CYP3A5*2 allele
CC: normal
rs28362286CC10.0 (3.0)99.94PCSK9AA: Lowered LDL-C and lower risk for coronary events
AC: Lowered LDL-C and lower risk for coronary events
CC: common in complete genomics
rs17847577CC80.0 (7.5)99.93WRNCC: normal
CT: Unaffected carrier for Werner's Syndrome
TT: Werner's Syndrome
rs17646946AG1 (2.5)32.06TCHHL1AA: straighter curl
rs17602729CC
GG
10.0 (3.5)79.02AMPD1AA: AMPD1 deficiency homozygous (orientation reversed)
AC: unexpected genotype
AG: AMPD1 deficiency heterozygous (orientation reversed)
AT: Really unexpected!
CC: normal
CG: unexpected genotype
CT: AMPD1 deficiency heterozygous
GG: normal (orientation reversed)
GT: unexpected genotype
TT: AMPD1 deficiency homozygous
rs17487223CC150.0 (2.5)43.82CHRNB4CC: normal
CT: Higher lung cancer risk?
TT: 1.28x lung cancer risk
rs17228212TT150.0 (2.0)56.39SMAD3CC: >1.26x increased risk for heart disease
CT: 1.26x increased risk for heart disease
TT: normal
rs17115100GG100.0 (2.0)79.34CYP17A1GG: common on affy axiom data
GT: slightly increased risk of developing Parkinson's Disease
TT: Increased risk of developing Parkinson's Disease
rs17036170GG30.0 (2.0)96.69PPARGAA: Elevated risk for drug induced liver injury with diclofenac
AG: Increased risk of drug induced liver injury with diclofenac
GG: Normal risk of drug induced liver injury with diclofenac
rs16991615GG200.0 (1.5)89.05MCM8AA: age at menopause increased by avg of 22 months
AG: slight increase (11 months) in avg age at menopause
GG: common on affy axiom data
rs16990018AA200.0 (2.0)99.69PRNPAA: PrP Codon 171 Asn - Non-pathogenic variant
AG: PrP 171 N/S Heterozygote - Unknown significance
rs16969968GG150.0 (3.0)45.93CHRNA5AA: higher risk for nicotine dependence, lower risk for cocaine dependence
AG: slightly higher risk for nicotine dependence, lower risk for cocaine dependence
GG: normal
rs16910526AA120.0 (3.0)85.19CLEC7AAA: common on affy axiom data
rs16901979CC80.0 (2.9)89.54AA: 1.5x increased risk for prostate cancer
AC: 1.5x increased risk for prostate cancer
CC: normal risk
rs16892766AA80.0 (2.0)85.28AA: common in complete genomics
AC: slight (~1.5x) increase in colorectal cancer risk
CC: slight (~2x) increase in colorectal cancer risk
rs16890979CC40.0 (2.0)57.30SLC2A9CC: 3.4x risk of gout
CT: 1.7x risk of gout
TT: lower systolic blood pressure, serum uric acid and gout risk
rs16847548TT10.0 (2.5)58.60CC: 2.6x increased risk for sudden cardiac death in Caucasians
CT: 1.3x increased risk for sudden cardiac death in Caucasians
TT: normal
rs13387042GG20.0 (1.2)24.36AA: 1.24x increased risk for breast cancer
AG: 1.12x increased risk for breast cancer
GG: normal
rs13376333CC10.0 (2.0)50.85KCNN3CT: 1.5x higher risk of atrial fibrillation
TT: ~2x higher risk of atrial fibrillation
rs13361189TT50.0 (2.6)79.39CC: 2.6x increased risk for Crohn's disease
CT: 1.3x increased risk for Crohn's disease
TT: normal
rs13357391CC50.0 (0.0)9.42SPOCK1CC: slightly earlier age at menarche
CT: normal
TT: normal
rs12948217CT170.0 (2.5)41.32ASPAAA: can be ignored for now
AC: carrier for Canavan disease
AT: carrier for Canavan disease
CC: common in clinvar
rs12777823GG100.0 (3.5)70.50LOC100130970AA: Avoid Plavix, higher risk for adverse cardiovascular events. CYP2C19 poor metabolizer.
AG: Avoid Plavix, higher risk for adverse cardiovascular events.
rs12770228GG100.0 (2.0)47.68C10orf114AA: 2x increased risk for meningioma
AG: 1.4x increased risk for meningioma
rs12720461CC150.0 (2.0)99.69CYP1A2CC: normal
CT: carrier of one CYP1A2*1K_-729C>T allele, decreased CYP1A2 activity
TT: CYP1A2*1K_-729C>T homozygote, decreased CYP1A2 activity
rs12708716GG160.0 (0.0)14.66CLEC16AAA: 1.6x risk of type-1 diabetes
AG: 1.2x risk of type-1 diabetes
GG: normal
rs12678919AA80.0 (2.0)82.82AA: common on affy axiom data
AG: associated with higher HDL cholesterol
GG: associated with higher HDL cholesterol
rs12567232GG10.0 (2.0)45.18AA: Increased risk for Crohn's Disease
AG: Increased risk for Crohn's Disease
GG: normal
rs12536657GG70.0 (2.5)65.80HGFAA: hypermyopia risk
rs12510549TT4 (1.0)61.65CC: Decreased risk for high uric acid levels and gout
rs12483377GG210.0 (1.0)85.22COL18A1AA: no significant effect
GG: common in clinvar
rs12255372GG100.0 (3.5)53.85TCF7L2GG: normal
GT: 1.3x increased type-2 diabetes risk
TT: increased breast cancer, type-2 diabetes, and aggressive prostate cancer risk
rs12210050CC60.0 (1.5)75.64CC: common on affy axiom data
CT: Slightly higher risk for basal cell carcinoma
TT: Slighly higher risk for basal cell carcinoma
rs12193446AA60.0 (2.0)84.66LAMA2GG: lower risk of nearsightedness
rs12050604CC150.0 (1.2)45.86UBR1AA: slightly increased risk for lung cancer
AC: very slightly increased risk for lung cancer
rs12021720CC10.0 (0.1)82.06DBTTT: rare genotype but harmless
rs11978267AG7 (2.0)37.04IKZF1AA: normal/common
GG: possible increased risk for infant acute myeloid leukemia (AML)
rs11887534GG20.0 (2.1)88.35ABCG8CC: 7x increased risk for gallstones
CG: 2x increased risk for gallstones
GG: normal risk for gallstones
rs11803731AT1 (2.0)30.32TCHHAA: straighter hair
TT: curlier hair
rs11662595AA180.0 (2.0)82.04HRH4AA: common on affy axiom data
rs11649743GG17 (2.5)67.06HNF1BAA: Lower prostate cancer risk?
rs11636232CT15 (1.0)40.26HERC2CC: darker eye color
TT: lighter eye color
rs11622475TT140.0 (0.0)9.40TDRD9CC: 1.5x risk
CT: 1.1x risk
TT: normal
rs11614913CT120.0 (3.0)48.24MIR196A2CC: increased risk of various types of cancer
CT: normal
TT: decreased risk for colorectal cancer and lung cancer
rs11591147GG10.0 (4.5)97.18PCSK9GG: normal
GT: 2-3 fold lower risk of heart disease
TT: 2-3 fold lower risk of heart disease
rs11571833AA130.0 (2.0)98.56BRCA2AA: common in complete genomics
rs11571747AA130.0 (2.0)99.54BRCA2AA: common in complete genomics
rs11549407CC
GG
110.0 (3.5)99.93HBBCC: common in complete genomics
CT: Beta Thalassemia carrier, Beta Thalassemia intermedia, Hemoglobin beta-zero, nonsense mutation
TT: Beta Thalassemia major, Hemoglobin beta-zero, nonsense mutation
rs11547464GG160.0 (3.5)98.62MC1RAA: red hair
AG: red hair carrier
GG: normal
rs11523871AA100.0 (1.6)48.12DMBT1AA: normal
AC: 1.6x increased breast cancer risk for women over 60
CC: >1.6x increased breast cancer risk for women over 60
rs11466023CC
GG
160.0 (2.0)97.43MEFVCC: common in clinvar
CT: carrier of a variant related to a mild form of familial Mediterranean fever
TT: mild familial Mediterranean fever
rs11229030CT11 (2.0)47.28CC: higher odds of Crohn's disease
rs11200638GG100.0 (3.5)56.98HTRA1AA: ~10x increased risk of wet age related macular degeneration
AG: ~2x increased risk of age related macular degeneration
GG: normal
rs11172113TT12 (1.2)38.26LRP1CC: 0.8x lower risk for migraines
CT: 0.9x lower risk for migraines
rs11170164GG
CC
120.0 (2.0)86.98KRT5AA: 1.35x risk of basal cell carcinoma
GG: common on affy axiom data
rs11073328CC150.0 (2.0)80.97FAM98BCC: normal
TT: increased longevity?
rs10994336CC100.0 (2.0)84.94ANK3CC: common on affy axiom data
CT: 1.45x increased odds of developing bipolar disorder
TT: 2.9x increased odds of developing bipolar disorder
rs10937823CC40.0 (2.0)87.85SORCS2CC: normal
CT: some association with bipolar disorder
TT: some association with bipolar disorder
rs10911193CC10.0 (1.9)76.94LAMC1
rs10892759AG110.0 (1.0)46.07SORL1AA: reduced risk for Alzheimers?
AG: normal
GG: normal
rs10865331GG20.0 (1.4)37.08AA: 1.4x higher risk for ankylosing spondylitis
AG: 1.2x higher risk for ankylosing spondylitis
GG: normal risk ankylosing spondylitis
rs10859871AA120.0 (1.5)45.16AA: common/normal
AC: Slight (~1.2x) increase in endometriosis risk
CC: Slight (~1.4x) increase in endometriosis risk
rs10816625AA90.0 (1.5)85.22AA: common/normal
AG: slightly increased risk for breast cancer (1.12x)
GG: slightly increased risk for breast cancer (1.24x)
rs10801935AA10.0 (1.6)40.69VTCN1AA: normal
AC: normal
CC: 0.3x decreased risk of breast cancer
rs10759932TT90.0 (2.0)77.38TLR4CC: increased risk for chorionic plate inflammation
CT: increased risk for chorionic plate inflammation
TT: normal
rs10754339AA10.0 (1.4)81.78VTCN1AA: normal
AG: 1.3x increased risk of breast cancer
GG: 1.45x increased risk of breast cancer
rs10748045AA12 (2.5)40.59GRIP1GG: 1.78x risk of Suicidal ideation in depression or bipolar disorder
rs10509681TT100.0 (2.0)80.28CYP2C8TT: common on affy axiom data
rs10509680GG100.0 (3.0)88.50CYP2C9GG: common on affy axiom data
rs10503669CC80.0 (2.0)81.83AA: associated with higher HDL cholesterol
AC: associated with higher HDL cholesterol
rs10499194CC60.0 (2.0)54.70CC: normal
TT: protective against rheumatoid arthritis for asians
rs10490924GG100.0 (3.5)60.09ARMS2GG: normal
GT: 2.7x risk for age related macular degeneration
TT: 8.2x risk for age related macular degeneration
rs10485057AA60.0 (3.0)84.03OPRM1AA: normal
AG: normal?
GG: increased risk for smoking, nicotine dependence
rs10468017CC15 (2.0)54.54LOC102724766CT: associated with higher HDL cholesterol
TT: associated with higher HDL cholesterol
rs10427255CT2 (2.1)50.00CC: highest odds of photic sneeze reflex
TT: lowest odds of photic sneeze reflex
rs10411210CC190.0 (2.1)75.39RHPN2TT: 1.15x increased risk of colorectal cancer
rs10127939GT
AC
1 (1.0)7.54FCGR3AAA: immunodeficiency, but not for 23andMe users
TT: common in clinvar
rs10090154CC80.0 (2.1)80.76CC: normal
CT: 1.4x increased risk for prostate cancer
TT: 1.4x increased risk for prostate cancer
rs10088218GG80.0 (2.0)77.57LINC00824AA: 0.5x decreased risk for ovarian cancer
AG: 0.76x decreased risk for ovarian cancer
rs10086908TT80.0 (2.0)52.16CC: 1.7x increased risk for prostate cancer
CT: 1.7x increased risk for prostate cancer
TT: normal risk
i5012880II (3.0)99.86DI: carrier for glycogen storage disease type 1b allele
i5012759AA0.0 (4.0)99.33AA: normal
AG: Carrier of Medium-Chain Acyl-CoA Dehydrogenase Deficiency
GG: Medium-Chain Acyl-CoA Dehydrogenase Deficiency
i5012758TT0.0 (4.0)99.87CC: Medium-Chain Acyl-CoA Dehydrogenase Deficiency
CT: Carrier of Medium-Chain Acyl-CoA Dehydrogenase Deficiency
TT: normal
i5012688CC0.0 (5.0)99.66CC: normal
CT: Zellweger Syndrome Spectrum carrier
TT: Zellweger Syndrome Spectrum
i5012680GG0.0 (5.0)99.06AA: Congenital Disorder of Glycosylation Type 1a (PMM2-CDG)
AG: Congenital Disorder of Glycosylation Type 1a carrier
GG: normal
i5012672GG0.0 (5.0)99.80AA: epidermolysis bullosa
AG: carrier of epidermolysis bullosa allele
GG: common/normal
i5012669GG0.0 (5.0)99.93AA: epidermolysis bullosa
AG: carrier of epidermolysis bullosa allele
GG: common/normal
i5012664GG0.0 (5.0)99.93CC: Hereditary Fructose Intolerance
CG: Hereditary Fructose Intolerance carrier
GG: normal
i5012634GG0.0 (5.0)99.93AA: Salla Disease
AG: Salla Disease carrier
GG: normal
i5012628II0.0 (5.0)99.93DD: Primary hyperoxaluria type 2
DI: carrier of Primary hyperoxaluria type 2 allele
II: common/normal
i5012624GG0.0 (5.0)99.93AA: Neuronal Ceroid Lipofuscinosis (PPT1-related)
AG: Neuronal Ceroid Lipofuscinosis carrier
GG: normal
i5012618AA0.0 (5.0)99.93AA: normal
AC: Pendred Syndrome carrier
CC: Pendred Syndrome
i5012070DD (3.0)99.86DI: Carrier of a cystic fibrosis allele
i5011913GG (3.0)99.60CG: Carrier of a cystic fibrosis allele
i5011483AA (4.0)99.87AG: cystic fibrosis carrier
i5008215GG0.0 (5.0)99.87GG: normal
GT: Hereditary Fructose Intolerance carrier
TT: Hereditary Fructose Intolerance
i5006133CC (3.0)99.87CT: Carrier of a cystic fibrosis allele
i5006120GG (3.0)89.54AG: Carrier of a cystic fibrosis allele
i5006101TT0.0 (4.0)99.93GT: carrier of a cystic fibrosis allele
TT: common/normal
i5006053AA (3.0)99.93AC: Carrier of a cystic fibrosis allele
i5005437AA (3.0)86.79AT: Carrier of allele for congenital adrenal hyperplasia
i5005430GG (3.0)99.93AG: Carrier of allele for congenital adrenal hyperplasia
i5003264GG0.0 (5.0)99.93AA: Myotonia congenita, Thomsen's disease
AG: Myotonia congenita, Thomsen's disease
GG: normal
i5000099G (4.0)99.94AA: MELAS syndrome
i4000478CC0.0 (5.0)99.94CC: normal
CT: Phenylketonuria carrier
TT: Phenylketonuria
i4000475AA0.0 (5.0)99.87AA: normal
AC: Phenylketonuria carrier
CC: Phenylketonuria
i4000472AA0.0 (5.0)99.94AA: normal
AG: Phenylketonuria carrier
GG: Phenylketonuria
i4000462II0.0 (3.0)99.81DI: increased risk of breast and prostate cancer
II: common/normal
i4000446II0.0 (7.0)99.94DD: Torsion dystonia
DI: torsion dystonia
II: common/normal
i4000442GG0.0 (2.0)99.31AA: likely to lead to a false positive blood test for Tay Sachs
AG: likely to lead to a false positive blood test for Tay Sachs
GG: normal
i4000440GG0.0 (2.0)99.94AA: likely to lead to a false positive blood test for Tay Sachs disease
AG: likely to lead to a false positive blood test for Tay-Sachs Disease
GG: normal
i4000438CC0.0 (5.0)99.69CC: normal
CT: Tay-Sachs Disease carrier
TT: Tay-Sachs Disease
i4000436CC0.0 (5.0)99.94CC: normal
CT: Tay-Sachs Disease carrier
TT: Tay-Sachs Disease
i4000435II0.0 (4.0)99.81DD: deafness-associated
DI: carrier for deafness-associated variant
i4000434II0.0 (4.0)98.68DD: deafness associated
DI: carrier of most common deafness-associated variant in Caucasians
i4000425AA0.0 (5.0)99.94AA: normal
AG: Mucolipidosis IV carrier
GG: Mucolipidosis IV
i4000415TT0.0 (6.0)99.31CC: Gaucher's disease
CT: carrier for Gaucher's disease; increased risk for Parkinsons disease
TT: normal
i4000412GG0.0 (5.0)99.94AA: Fanconi Anemia (FANCC-related)
AG: Fanconi Anemia carrier
GG: normal
i4000410CC0.0 (5.0)99.94CT: carrier of familial mediterranean fever
TT: familial mediterranean fever
i4000407TT0.0 (3.0)98.68CT: carrier of possible familial mediterranean fever allele
i4000406TT0.0 (5.0)99.87CC: familial mediterranean fever
CT: carrier of familial mediterranean fever allele
TT: common/normal
i4000399TT0.0 (5.0)99.75CC: Factor XI Deficiency
CT: Factor XI Deficiency carrier
TT: normal
i4000398GG0.0 (5.0)99.94GG: normal
GT: Factor XI Deficiency carrier
TT: Factor XI Deficiency
i4000391DD0.0 (5.0)99.75DD: common/normal
DI: Tay Sachs disease allele carrier
II: Tay Sachs
i4000381TT0.0 (5.0)99.94CC: Niemann-Pick Disease Type A
CT: Niemann-Pick Disease Type A carrier
TT: normal
i4000377II0.0 (10.0)99.87DD: BRCA1 (breast cancer) 185delAG homozygous carrier
DI: BRCA1 (breast cancer) 185delAG carrier
i4000336TT0.0 (5.0)99.94AA: Fanconi Anemia (FANCC-related)
AT: Fanconi Anemia carrier
TT: normal
i4000334AA0.0 (5.0)99.94AA: normal
AG: Familial dysautonomia carrier
GG: Familial dysautonomia
i4000325CC0.0 (5.0)99.87CC: normal
CT: Cystic Fibrosis carrier
TT: Cystic Fibrosis
i4000317GG0.0 (5.0)99.94AA: Cystic Fibrosis
AG: Cystic Fibrosis carrier
GG: normal
i4000308CC0.0 (5.0)99.94CC: normal
CT: Cystic Fibrosis carrier
TT: Cystic Fibrosis
i4000305GG0.0 (5.0)99.87AA: a treatable form of cystic fibrosis
AG: carrier for cystic fibrosis
GG: normal
i4000300GG0.0 (5.0)99.81GG: normal
GT: Cystic Fibrosis carrier
TT: Cystic Fibrosis
i4000299GG0.0 (5.0)99.94GG: normal
GT: Cystic Fibrosis carrier
TT: Cystic Fibrosis
i4000297GG0.0 (5.0)99.94AA: Cystic Fibrosis
AG: Cystic Fibrosis carrier
CC: Cystic Fibrosis
CG: Cystic Fibrosis carrier
GG: normal
i4000295GG0.0 (3.0)99.75AG: unaffected carrier of cystic fibrosis allele
GG: common/normal
i3003626II0.0 (5.0)81.40DD: resistant to HIV
i3003405TT0.0 (5.0)99.87CC: Phenylketonuria
CT: Phenylketonuria carrier
TT: normal
i3003401GG0.0 (5.0)99.94AA: Phenylketonuria
AG: Phenylketonuria carrier
GG: normal
i3003137TT0.0 (4.0)99.81AA: Sickle Cell Anemia
AT: Sickle Cell Anemia carrier; malaria resistance
TT: normal
i3002517TT0.0 (5.0)99.87AA: Rhizomelic Chondrodysplasia Punctata Type 1 (RCDP1)
AT: Rhizomelic Chondrodysplasia Punctata Type 1 carrier
TT: normal
i3002468AA0.0 (4.0)96.68AA: normal
AT: Hemochromatosis carrier
TT: Hemochromatosis (HFE-related)
i3002449CC (3.0)99.94CT: Carrier of a cystic fibrosis allele
i3002432GG0.0 (3.0)97.50AA: increased risk of venous thromboembolism
AG: increased risk of venous thromboembolism
i3000001II0.0 (5.0)98.18DD: Cystic Fibrosis
DI: Cystic Fibrosis carrier
rs9960767AA180.0 (1.4)85.81TCF4AA: normal
AC: 1.2x increased risk for schizophrenia
CC: 1.4x increased risk for schizophrenia
rs9934438GG160.0 (2.5)35.90VKORC1AA: coumadin resistance
rs9923231CC160.0 (2.1)35.99VKORC1CC: normal
CT: reduced warfarin dose if treated for VTE
TT: reduced warfarin dose if treated for VTE
rs9834312AA30.0 (0.0)15.02FLNBAA: normal
AG: None
GG: taller
rs9550642AG130.0 (0.0)19.80LOC100133618AA: 2.2x risk
AG: 1.3x risk
GG: normal
rs9543325CT13 (2.0)44.77CC: Slightly higher pancreatic cancer risk
rs9536314TT130.0 (2.7)76.77KLGG: worse cognitive function
GT: intelligence; longevity
TT: most common in all populations
rs9525638CT13 (2.0)46.75CC: stronger bones
TT: weaker bones
rs9332964GG
CC
20.0 (4.0)99.94SRD5A2AA: micropenis
AG: carrier for mutations linked to micropenis
GG: average
rs9332739GG60.0 (2.0)91.48C2CC: reduced risk of age related macular degeneration
CG: None
GG: normal
rs9306160CC210.0 (1.3)39.93RRP1BCC: normal
CT: 0.75x (reduced) risk for metastasis in LN-/ER+ breast cancer patients
TT: 0.75x (reduced) risk for metastasis in LN-/ER+ breast cancer patients
rs9272346GG60.0 (2.7)17.83HLA-DQA1AA: 18.5x risk of Type-1 Diabetes
AG: 5.5x risk type-1 diabetes
GG: normal
rs8192466CC
GG
110.0 (4.0)99.50BDNFCC: common
CT: None
TT: None
rs8177374CC110.0 (3.5)73.45TIRAPCC: common on affy axiom data
TT: resistance to several diseases
rs8176058CC
GG
70.0 (2.5)93.74KELCC: common
CT: KELL K/k BLOOD GROUP carrier
TT: KELL K/k BLOOD GROUP
rs8099917TT190.0 (3.0)64.06GG: lower odds of responding to PEG-IFNalpha/RBV treatment
GT: Moderately lower odds of responding to PEG-IFNalpha/RBV treatment
TT: common
rs8070723AA170.0 (2.5)63.37MAPTAG: 0.18x reduced risk of developing progressive supranuclear palsy
GG: ~0.05x (thus greatly) reduced risk for developing progressive supranuclear palsy
rs8069176AA170.0 (0.0)18.82AA: normal
AG: normal
GG: if 4 years old or younger, ~3x increased asthma risk if exposed to smoke
rs8034191TT150.0 (2.6)44.96AGPHD1CC: 1.80x lung cancer risk; decreased response to alcohol
CT: 1.27x lung cancer risk
TT: normal
rs7984966CT13 (2.5)38.14HTR2ACC: ADHD in adults
rs7961152CC120.0 (2.0)31.58BCAT1AA: 1.5x higher risk for hypertension
AC: 1.2x higher risk for hypertension
CC: normal
rs7913069CC100.0 (2.2)95.30LOC102724351CC: normal
CT: 1.47x risk for uterine fibroids
rs7754840GG60.0 (3.0)46.30CDKAL1CC: 1.3x increased risk for type-2 diabetes
CG: 1.3x increased risk for type-2 diabetes
GG: normal
rs7705924AA50.0 (2.5)92.20LINC00492AA: common in complete genomics
GG: higher odds of Crohn's disease
rs7652331TT30.0 (0.0)11.91FYCO1CC: normal risk
CT: normal risk
TT: somewhat higher risk for prostate cancer
rs7651446GG30.0 (2.2)91.07TIPARPGG: common/normal
GT: 1.5x increased risk for epithelial ovarian cancer
TT: 2.25x increased risk for epithelial ovarian cancer
rs7626962GG30.0 (4.0)99.48SCN5AGG: common in clinvar
GT: increased susceptibility to long QT syndrome
TT: increased susceptibility to long QT syndrome
rs7611694AC3 (1.1)49.18SIDT1CC: Lower prostate cancer risk?
rs7566605GG20.0 (0.2)44.96CC: mixed evidence of increased obesity risk, may suppress excercise effects in men
CG: ?
GG: common
rs7501331CC160.0 (2.0)59.13BCMO1CC: normal
CT: Reduced conversion of beta-carotene to retinol
TT: Reduced conversion of beta-carotene to retinol
rs7454108TT60.0 (1.5)81.92CC: Homozygous for HLA-DQ8 haplotype
CT: Single HLA-DQ8 haplotype
TT: common in complete genomics
rs7349332CC20.0 (2.5)75.95WNT10ACC: straighter hair; common
TT: hair curl
rs7326018TT130.0 (0.0)16.59AA: normal
AT: normal
TT: 1.8x increased risk for multiple sclerosis
rs7294919TT120.0 (3.0)79.43CC: Enhanced hippocampal volume
CT: Moderately enhanced hippocampal volume
TT: Average hippocampal volume
rs7270101AA200.0 (3.3)77.71ITPACC: causative. Ribavirin-induced anemia iRibavirin-induced anemia during anti-hepatitis C virus therapy
rs7250581AG190.0 (2.0)25.56AA: normal
AG: normal
GG: 1.4x risk
rs7190458GG16 (2.1)90.76BCAR1AA: Higher pancreatic cancer risk
AG: Slightly higher pancreatic cancer risk
rs7080536GG100.0 (3.0)92.92HABP2AA: carotid stenosis, thrombophilia
AG: carrier for carotid stenosis, thrombophilia
GG: common in clinvar
rs7076156AG10 (2.0)37.59ZNF365
rs6994992CC8 (1.0)35.32NRG1TT: increased creativity?
rs6974491GG70.0 (1.5)72.76ELMO1AA: Higher risk of coeliac and/or inflammatory bowel disease
AG: Higher risk of coeliac and/or inflammatory bowel disease
GG: common on affy axiom data
rs6922269AG60.0 (2.0)38.35MTHFD1LAA: 1.6x risk
AG: 1.2x risk
GG: normal
rs6910071AA60.0 (2.0)67.00C6orf10AA: normal
AG: possibly at 4x higher risk of [[rheumatoid arthritis]]
GG: 6x higher risk of rheumatoid arthritis
rs6897876TT50.0 (1.2)19.73CC: >3x increased testicular cancer risk for men
CT: 3x increased testicular cancer risk for men
TT: normal
rs6800901CC3 (1.1)47.58POLQCT: multiple myeloma risk ?
TT: 1.3x multiple myeloma risk
rs6797312TT30.0 (0.0)16.09SERPINI1AA: 2x higher stroke risk in Caucasian women
AT: 2x higher stroke risk in Caucasian women
TT: normal
rs6746030GG20.0 (1.0)75.08SCN9AAA: Increased perception of pain
AG: reported to influence perception of pain
GG: Normal perception of pain
rs6742078GG20.0 (2.1)44.96UGT1A10GG: normal
TT: +16% bilirubin levels increased risk of gallstones
rs6679677CC10.0 (3.0)83.52RSBN1AA: 5.2x risk for T1D; 3.3x for RA
AC: 1.8x risk for T1D; 2x risk for RA
CC: normal
rs6604026TT10.0 (2.0)52.47RPL5CC: >1.15x risk
CT: 1.15x risk
TT: common
rs6602024AG100.0 (0.0)17.73PFKPAA: 1-3 body mass index units heavier on average
AG: ?
GG: normal
rs6596189CT5 (2.0)21.85PITX1
rs6511720GG190.0 (2.0)80.19LDLRGG: common in complete genomics
GT: Slightly lower odds of developing CHD.
TT: Slightly lower odds of developing CHD.
rs6495446CT150.0 (1.4)38.95MTHFSCC: 2.5x increased risk for chronic kidney disease
CT: 1.2x increased risk for chronic kidney disease
TT: normal
rs6471482CC80.0 (1.5)71.37CNGB3CC: common on affy axiom data
rs6449213TT40.0 (2.0)62.87SLC2A9CC: ~4x higher risk for hyperuracemia
CT: ~2x higher risk for hyperuracemia
TT: normal
rs6445975GT3 (2.0)40.58PXKGG: disease risk associated
rs6435862TT20.0 (2.0)52.44BARD1GG: 2.8x higher risk of aggressive neuroblastoma
GT: 1.7x higher risk of aggressive neuroblastoma
TT: Normal risk of aggressive neuroblastoma.
rs6413420GT100.0 (0.0)9.47CYP2E1GG: normal
GT: carrier of one CYP2E1*7_-71G>T allele
TT: CYP2E1*7_-71G>T homozygote
rs6060369CC200.0 (2.0)15.96UQCCCC: 0.88cm taller
CT: 0.44cm taller
TT: normal height
rs5968255CTX (1.5)10.03CC: slower AIDS progression
TT: common, but faster HIV progression
rs5963409AGX0.0 (0.0)17.05OTCAA: 1.19x increased risk for Alzheimer's disease
AG: 1.19x increased risk for Alzheimer's disease
GG: normal
rs5945572AGX (1.1)18.37AA: Higher prostate cancer risk ?
rs5770917CT220.0 (0.0)11.36CHKBCC: >1.4x increased risk for narcolepsy
CT: 1.4x increased risk for narcolepsy
TT: normal
rs5759167GT22 (2.0)49.84TT: Higher prostate cancer risk
rs5743618GT
AC
4 (2.0)81.82TLR1GG: greater resistance to leprosy; but also consequence for Lyme patients
rs5743289CT16 (1.0)25.44NOD2CC: common on affy axiom data
TT: Risk for IBD
rs5742905TT
AA
210.0 (3.5)99.50CBSCC: Mild clinical homocystinuria which is responsive to vitamin B6
CT: carrier for Mild clinical homocystinuria which is responsive to vitamin B
TT: common in clinvar
rs5742904GG
CC
20.0 (4.0)99.75AA: Hypercholesterolemia, Type B; homozygote
AG: Hypercholesterolemia, Type B; heterozygote
GG: normal
rs5031017GG
CC
190.0 (2.0)46.92CYP2A6GG: normal
GT: One copy of CYP2A6*5 non-functioning variant; impaired nicotine metabolism
TT: Two copies of CYP2A6*5 non-functioning variant; impaired nicotine metabolism
rs5030868CC
GG
X0.0 (6.0)39.85G6PDCC: common in clinvar
CT: G6PD Heterozygous
TT: Homozygous/Hemizygous mutant
rs5030867AA
TT
220.0 (4.0)99.75AA: normal
AC: carrier of one CYP2D6*7 allele
CC: CYP2D6*7 homozygote
rs5030860AA
TT
120.0 (6.0)99.87PAHAA: common in clinvar
AG: carrier of Phenylketonuria allele
GG: Phenyketonuria
rs5030858CC
GG
120.0 (6.0)99.62PAHCC: common in clinvar
CT: carrier of Phenylketonuria allele
TT: Phenylketonuria
rs5030857CC
GG
120.0 (6.0)99.62PAHCC: common in clinvar
CT: carrier of Phenylketonuria allele
TT: Phenylketonuria
rs5030853GG
CC
120.0 (6.0)99.75PAHGG: common in clinvar
GT: carrier of Phenylketonuria allele
TT: Phenylketonuria
rs5030849GG
CC
120.0 (6.0)99.87PAHAA: PHENYLKETONURIA, MILD
AG: carrier for a mild form of PHENYLKETONURIA
GG: common in clinvar
rs5030841TT
AA
120.0 (6.0)99.94PAHCC: Phenylketonuria
CT: carrier of Phenylketonuria allele
TT: common in clinvar
rs4987117CC130.0 (2.0)95.96BRCA2CC: common in complete genomics
rs4986893GG100.0 (2.1)99.50CYP2C19AA: poor metabolizer of several commonly prescribed drugs
AG: carrier of a CYP2C19*3 allele, a "slow metabolizer" allele
GG: normal
rs4986852GG
CC
170.0 (2.0)96.99BRCA1AA: predisposition to breast cancer?
AG: possible predisposition to breast cancer
GG: normal
rs4986850GG
CC
170.0 (2.0)85.84BRCA1GG: common in complete genomics
rs4986791CC90.0 (2.5)88.79TLR4CC: normal
CT: complex; see details
TT: complex; see details
rs4986790AA90.0 (2.5)88.67TLR4AA: normal
AG: None
GG: complex; numerous associations reported
rs4986782GG80.0 (3.5)97.06NAT1AA: slow acetylator = higher risk of smoking-induced lung cancer
AG: slow acetylator = higher risk of smoking-induced lung cancer
GG: common in complete genomics
rs4977574AA90.0 (1.5)27.44CDKN2B-AS1AA: common
AG: Some studies - but not others - report a slightly increased risk for myocardial infarction
GG: Most studies find a somewhat elevated (~1.5x) risk for myocardial infarction
rs4969168GG17 (2.3)71.87SOCS3AA: Obesity and/or Insulin resistance associations
rs4968451AA170.0 (2.1)73.14BRIP1AA: Normal risk for meningioma
AC: 1.61x increased risk for meningioma
CC: 2.33x increased risk for meningioma
rs4959039AA60.0 (1.6)54.52AA: normal
AG: 1.4x higher risk for multiple sclerosis
GG: 1.6x higher risk for multiple sclerosis
rs4915077TT10.0 (2.0)82.03VAV3CC: Higher risk of hypothyroidism
rs4911414GG200.0 (2.0)49.03GG: normal
GT: 2-4x higher risk of sun sensitivity if part of risk haplotype
TT: 2-4x higher risk of sun sensitivity if part of risk haplotype
rs4825476AGX0.0 (2.0)15.23GRIA3AA: normal
AG: normal
GG: 1.9x higher risk of suicidal thoughts when taking [[citalopram]]
rs4795400TT170.0 (0.0)18.34GSDMBCC: normal
CT: normal
TT: if 4 years old or younger, ~2.5x increased asthma risk if exposed to smoke
rs4785763CC160.0 (1.5)46.78AFG3L1AA: 2x higher risk for melanoma
AC: 1.5x higher risk for melanoma
CC: common
rs4730751CC70.0 (2.0)58.13CAV1AA: For kidney donors, 2x more likely to result in allograft rejection
rs4693596CT4 (2.1)45.21COQ2CC: 2x odds of myopathy if taking statins
rs4656461AA10.0 (2.2)78.03AA: normal
AG: 1.5x increased risk for open angle glaucoma
GG: 2.2x increased risk for open angle glaucoma
rs4654748TT10.0 (2.0)24.22NBPF3CC: 2.90 ng/mL lower Vitamin B6 blood concentration
CT: 1.45 ng/mL lower Vitamin B6 blood concentration
TT: normal Vitamin B6 blood concentration
rs4648317CC
GG
110.0 (1.2)71.82DRD2CC: normal
CT: prone to higher nicotine dependence?
TT: prone to higher nicotine dependence, more impulsive/sensation seeking
rs4648022CC40.0 (1.4)84.33NFKB1CC: Normal risk for NHL. The minor, protective allele is rare.
CT: 0.58x reduced risk of NHL
TT: 0.47x reduced risk for NHL
rs4516035CC120.0 (0.0)16.73VDRCC: if less milk in teenage females, less bone?
CT: if less milk in teenage females, less bone?
TT: normal
rs4496877GG70.0 (1.2)44.17NOS3GT: For type-1 diabetics, 1.3x increased nephropathy risk
TT: For type-1 diabetics, 1.6x increased nephropathy risk
rs4444903AA40.0 (2.1)32.60EGFAA: average
AG: 3.5x risk of hep-cancer in cirrhosis patients; higher glioma risk
GG: 3.5x risk of hep-cancer in cirrhosis patients; higher glioma risk; 3x higher gallbladder cancer risk in females
rs4410790CC7 (2.0)34.73
rs4363657TT120.0 (4.0)66.58SLCO1B1CC: 17x increased myopathy risk for statin users
CT: 4.5x increased myopathy risk for statin users
TT: normal
rs4320932AA
TT
110.0 (1.4)63.01INS-IGF2AA: normal
AG: 0.87x decreased risk for ovarian cancer
GG: 0.74x decreased risk for ovarian cancer
rs4295627TT80.0 (1.6)70.30GG: 1.6x higher risk for glioma development
GT: 1.3x higher risk for glioma development
rs4244285GG100.0 (4.0)70.81CYP2C19AA: poor metabolizer of several popular medicines; patients prescribed Plavix get less benefit, and have higher risk for adverse cardiovascular events
AG: poorer metabolizer of several popular medicines; patients prescribed Plavix get less benefit, and have higher risk for adverse cardiovascular events
GG: normal
rs4242382GG80.0 (2.0)79.59AA: 1.7x increased risk for prostate cancer
AG: 1.7x increased risk for prostate cancer
GG: normal risk
rs4149056TT120.0 (3.2)71.76SLCO1B1CC: 17x myopathy risk for statin users
CT: reduced breakdown of some drugs; 5x increased myopathy risk for statin users
TT: normal
rs4129148GGX0.0 (2.0)39.97CSF2RACC: >3x risk
CG: 3x risk of schizophrenia.
GG: common
rs3928305GMT (3.0)94.42MT-RNR2AA: Derived value
AG: Heteroplasmy
GG: Ancestral value
rs3918290GG
CC
10.0 (3.5)98.87DPYDAA: 5-fluorouracil toxicity
AG: some 5-fluorouracil toxicity
GG: common in complete genomics
rs3903239TT
AA
1 (3.0)33.29CC: higher frequency of atrial fibrillation
rs3892097AG
CT
220.0 (3.0)27.12CYP2D6AA: CYP2D6 poor metabolizer; many associations related to drug metabolism
AG: extensive metabolizer (usually)
GG: extensive metabolizer
rs3849942GG
CC
90.0 (1.4)58.81AA: 1.4x increased risk for ALS
AG: 1.2x increased risk for ALS
GG: normal
rs3848519CC180.0 (4.0)96.43FECHAA: erythropoietic protoporphyria likely
AC: carrier for an erythropoietic protoporphyria mutation
CC: common in complete genomics
rs3827760TT
AA
20.0 (2.0)92.98EDARCC: straighter, thicker hair, and increased odds of having shovel-shaped incisors
CT: increased odds of straighter, thicker hair as well as shovel-shaped incisors
TT: common in clinvar
rs3818361CC
GG
10.0 (1.2)61.19CR1CC: normal
CT: 1.15x increased risk for late-onset Alzheimer's
TT: 1.2x increased risk for late-onset Alzheimer's
rs3816873CT40.0 (2.2)38.32MTTPCC: reduced risk of type-2 diabetes
CT: None
TT: None
rs3815148AA70.0 (3.0)62.23COG5AA: normal
AC: 1.16x increased risk of Osteoarthritis
CC: 1.34x increased risk of Osteoarthritis
rs3814113CC90.0 (0.0)12.60CC: 0.8x decreased risk for ovarian cancer
CT: 0.8x decreased risk for ovarian cancer
TT: normal
rs3807153TT
AA
70.0 (1.0)89.79ATP6V0A4CC: benign
CT: carrier of a benign change
TT: normal
rs3804505CC
GG
60.0 (2.0)88.23EFHC1CC: common on affy axiom data
CT: ?
TT: rare, related to myoclonic epilepsy
rs3803662CC
GG
160.0 (3.0)52.54LOC643714CC: normal
CT: ?
TT: 1.6x increased risk for breast cancer
rs3798220TT60.0 (2.6)95.24LPACC: 2-3x higher risk for cardiovascular events, which can be lowered by aspirin
CT: 2-3x higher risk for cardiovascular events, which can be lowered by aspirin
TT: normal
rs3793784CC
GG
100.0 (2.0)36.93ERCC6CC: normal
CG: 1.5x risk for ARMD
GG: 1.6x risk for ARMD
rs3785143CC160.0 (1.0)82.25SLC6A2CC: normal risk of ADHD
CT: may be associated with ADHD
TT: may be associated with ADHD
rs3766379TT10.0 (0.0)18.69CD244CC: normal
CT: 1.37x increased risk for rheumatoid arthritis
TT: 1.9x increased risk for rheumatoid arthritis
rs3764261GG
CC
160.0 (2.5)46.65GT: associated with higher HDL cholesterol
TT: associated with higher HDL cholesterol. HDL = good
rs3761847AA90.0 (2.2)33.40TRAF1AA: normal
AG: 1.32 x risk of rheumatoid arthritis.
GG: >1.32 x risk of rheumatoid arthritis
rs3760511CC
GG
170.0 (1.2)12.92HNF1BAA: normal risk for prostate cancer
AC: 1.16x increased risk for prostate cancer
CC: 1.16x increased risk for prostate cancer
rs3758650GG110.0 (2.2)88.57CDHR5AA: 6x increased risk for gallstone disease in Taiwanese/Chinese
AG: 1.6x increased risk for gallstone disease in Taiwanese/Chinese
GG: common in complete genomics
rs3754777GG
CC
20.0 (1.5)67.63STK39AA: slightly higher blood pressure if Caucasian
AG: slightly higher blood pressure if Caucasian
GG: normal
rs3750817TT100.0 (0.0)17.03FGFR2CC: normal
CT: 0.78x reduced risk for breast cancer
TT: 0.64x reduced risk for breast cancer, and higher likelihood of favorable postmenopausal hormone therapy
rs3748079AA
TT
60.0 (0.0)4.95ITPR3AA: normal risk
AG: normal risk
GG: 1.9x increased risk for SLE (lupus)
rs3747742TT6 (2.0)49.09TREML2
rs3745274GT19 (2.0)37.15CYP2B6
rs3743930GG
CC
160.0 (2.1)94.48MEFVCC: some reports of familial Mediterranean fever
CG: weakly linked to familial mediterranean fever
GG: common in clinvar
rs3738414GG10.0 (1.6)95.63VTCN1AA: 0.4x decreased risk of breast cancer
AG: normal
GG: normal
rs3738401GG10.0 (2.0)50.47DISC1GG: common in clinvar
rs3736228CC110.0 (1.7)72.89LRP5CC: normal
CT: increased risk for osteoporosis
TT: increased risk for osteoporosis
rs3735684CC
GG
70.0 (1.0)87.53CYP2W1CC: common in complete genomics
CT: associated with increased colorectal cancer risk
TT: associated with increased colorectal cancer risk
rs3732379CC30.0 (3.0)55.60CX3CR1CT: reduced risk of acute coronary events
TT: increased susceptibility
rs3732378GG30.0 (3.0)70.88CX3CR1GG: common on affy axiom data
rs3731566GG100.0 (0.0)16.35ADD3AA: normal
AG: normal
GG: higher BP if rs4961(T) carrier
rs3197999CT
AG
3 (2.0)39.89MST1TT: 1.2x risk of Crohn's
rs3124314CT1 (2.0)48.86CC: curlier hair
TT: straighter hair
rs3117582AA
TT
60.0 (2.0)82.88BAT3AA: common on affy axiom data
CC: increased lung cancer risk
rs3093726TT60.0 (4.0)92.42TNFCC: Probably an HLA-B*5701 homozygote; high risk for hypersensitivity to various drugs including abacavir
CT: carrier. risk of toxicity from some medications
TT: normal
rs3093059TT
AA
1 (2.0)86.21CRPCC: associated with elevated C-reactive protein levels and hypertension
rs3025039CC60.0 (2.0)75.45VEGFACC: normal
CT: 2.6x increased risk for ARMD
TT: 2.6x increased risk for ARMD
rs3020314CC60.0 (0.0)15.09ESR1CC: 0.42x reduced lymphoma risk
CT: 0.64x reduced lymphoma risk
TT: normal
rs2987983TT
AA
140.0 (2.0)44.90ESR2CC: 1.2x increased risk of prostate cancer
CT: 1.2x increased risk of prostate cancer
TT: normal risk
rs2981745CC100.0 (1.6)49.64DMBT1CC: normal
CT: 1.6x increased risk for breast cancer in females over 60
TT: >1.6x increased risk for breast cancer in females over 60
rs2981582CC
GG
100.0 (3.2)37.09FGFR2CC: normal
CT: 1.3x higher risk of ER+ breast cancer
TT: 1.7x higher risk of ER+ breast cancer
rs2948694AA30.0 (2.0)78.52GHSRAA: normal
AG: increased risk for heavy alcohol consumption
GG: increased risk for heavy alcohol consumption
rs2854128AMT (1.0)36.16MT-RNR2AA: G2706A+, probably MT-Haplogroup H.
GG: G2706A-, not MT-Haplogroup H
rs2853499GMT (1.0)80.51MT-ND5AA: G12372A+, MT-Haplogroup U or K
GG: G12372A-, not MT-Haplogroup U or K
rs2853498AMT (1.5)80.70MT-L2AA: 12308-, not MT-Haplogroup U or K.
GG: 12308+, MT-Haplogroup U or K.
rs2853493AMT (1.0)81.01MT-ND4AA: A11467G-, not MT-Haplogroup U or K.
GG: A11467G+, MT-Haplogroup U or K
rs2844682CC
GG
60.0 (3.0)73.64CC: common in complete genomics
rs2837960TT210.0 (2.3)66.00LINC00323GG: 2.3x rheumatoid arthritis risk
GT: normal
TT: normal
rs2834167AG210.0 (2.1)37.51IL10RBAA: 2.67x increased risk for systemic sclerosis
AG: normal
GG: normal
rs2832407AC21 (2.0)45.04GRIK1CC: topiramate may work to reduce heavy drinking best for this genotype
rs2814707GG
CC
90.0 (1.2)58.86LOC102724192AA: >1.2x increased risk for ALS
AG: 1.2x increased risk for ALS
GG: normal
rs2802288GG60.0 (2.4)36.44FOXO3AA: longer lifespan
GG: normal
rs2764264TT6 (2.0)47.28FOXO3CC: greater odds of living to 95
rs2740574AA
TT
70.0 (2.0)91.11CYP3AAA: normal
AG: carrier of one CYP3A4*1B allele
GG: 2.5x increased risk for prostate or ovarian cancer; CYP3A4*1B homozygote
rs2735839GG190.0 (1.8)69.25KLK3AA: in prostrate cancer patients, this is statistically associated with a somewhat more aggressive cancer
AG: in prostrate cancer patients, this is statistically associated with a somewhat more aggressive cancer
rs2710102CC
GG
70.0 (2.0)26.11CNTNAP2CC: higher risk of speech development delay and/or impairment
CT: None
TT: Delayed childhood speech.
rs2665390TT30.0 (1.4)86.03TIPARPCC: 1.4x increased risk for ovarian cancer
CT: 1.2x increased risk for ovarian cancer
TT: common in complete genomics
rs2651899AA
TT
1 (1.2)31.12PRDM16AG: 1.1x higher risk for migraines
GG: 1.2x higher risk for migraines
rs2619522GT
AC
6 (2.0)31.56DTNBP1GG: associated with lower attention capacity but also a decrease in positive and paranoid schizotypy scores
rs2547231GT
AC
19 (2.0)27.80SULT2A1GG: Decreased levels of some blood metabolites
TT: Increased blood metabolite levels
rs2515641CT100.0 (2.0)22.06CYP2E1CC: normal
CT: carrier of one CYP2E1_10463T>C(F421F) allele
TT: CYP2E1_10463T>C(F421F) homozygote
rs2511989GG
CC
110.0 (2.2)36.48SERPING1AA: 0.44x decreased age-related macular degeneration risk
AG: 0.63x decreased age-related macular degeneration risk
GG: normal
rs2476601GG10.0 (3.2)83.47PTPN22AA: 2x risk of rheumatoid arthritis and other autoimmune diseases
AG: 2x risk for T1D, RA, Addison's
GG: Normal risk for autoimmune disorders
rs2472297CC150.0 (1.2)63.43CC: common on affy axiom data
CT: Associated with (slightly) increased coffee consumption
TT: Associated with (slightly) increased coffee consumption
rs2464196CC
GG
120.0 (2.0)47.03HNF1ACC: normal
CT: ~1.5x increased lung cancer risk
TT: ~2x increased lung cancer risk
rs2420946CC100.0 (2.1)35.92FGFR2CC: common
CT: 1.20x risk for breast cancer
TT: 1.64x risk for breast cancer
rs2395029TT60.0 (4.0)92.92HCP5GG: HLA-B*5701 homozygote; high risk for hypersensitivity to various drugs including abacavir; 2x psoriasis risk; see details
GT: HLA-B*5701 carrier
TT: common
rs2383207AA90.0 (2.1)22.10CDKN2BASAA: normal
AG: increased risk for heart disease
GG: increased risk for heart disease
rs2383206AA90.0 (3.0)23.62CDKN2BASAA: normal
AG: 1.4x increased risk for heart disease
GG: 1.7x increased risk for heart disease
rs2373115TT
AA
110.0 (0.1)4.20GAB2GT: normal
TT: normal
rs2361502TT20.0 (1.3)49.03HEATR7B1CC: Possible higher levels of serum bilirubin and lower risk for coronary artery disease
TT: common
rs2329340CT7 (1.0)46.80DDCTT: M
rs2313982CC
GG
40.0 (3.0)86.47CC: common in complete genomics
TT: Increases susceptibility to Parkinson's disease 2.0x
rs2306402TT100.0 (0.0)5.58CTNNA3CC: 1.18x increased risk for LOAD
CT: 1.18x increased risk for LOAD
TT: normal
rs2305795AG190.0 (2.0)49.59EIF3GAA: 1.3x higher risk of narcolepsy compared to (A;G) genotype
AG: normal risk of narcolepsy
GG: 0.75x risk of narcolepsy compared to (A;G) genotype
rs2305480TT
AA
170.0 (0.0)18.41GSDMBCC: normal
CT: normal
TT: if 4 years old or younger, ~3x increased asthma risk if exposed to smoke
rs2305089CT6 (2.2)47.87TTT: higher risk for chordoma
rs2301436GG
CC
60.0 (2.1)29.56FGFR1OP
rs2298566CC110.0 (2.0)56.61SNX19AA: normal
AC: increased risk of coronary heart disease; better response to statins
CC: increased risk of coronary heart disease; better response to statins
rs2295190GG60.0 (1.2)74.40SYNE1GG: common
GT: Slightly increased risk for ovarian cancer in women
TT: Slightly increased risk for ovarian cancer in women
rs2293347AG
CT
70.0 (1.1)19.55EGFRAA: normal
AG: normal
GG: among NSCLC patients, better Gefitinib response; common
rs2282679AA
TT
40.0 (1.5)52.44GCAA: normal
AC: somewhat lower vitamin D levels
CC: lower vitamin D levels
rs2281617CT6 (2.0)24.17OPRM1CC: Normal (better) response to amphetamine
rs2279744TT120.0 (2.1)38.63MDM2GG: Generally more cancer prone
GT: Generally more cancer prone; common
TT: normal
rs2278206TT
AA
20.0 (1.2)53.60INPP4ACC: 1.16x increased risk for asthma
CT: normal
TT: possibly less susceptible to asthma
rs2272783TT
AA
180.0 (4.0)88.84FECHCC: likely erythropoietic protoporphyria symptoms
CT: Low expression variant of FECH enzyme
TT: common in clinvar
rs2270954CC18 (2.0)72.89DCCAA: Possible increased susceptibility to schizophrenia
rs2270641TT80.0 (2.1)41.26SLC18A1GG: 3.7x higher risk for schizophrenia
GT: ?
TT: normal
rs2269475GG
CC
60.0 (1.8)76.52AIF1AA: increased rheumatoid arthritis risk
AG: increased rheumatoid arthritis risk
GG: normal
rs2267735GG70.0 (2.0)24.37ADCYAP1R1CC: Associated with PTSD, hyperarousal, impaired fear discrimination in traumatized females, but not males
CG: One copy of risk allele = associated with mildly increased chance of PTSD, hyperarousal, impaired fear discrimination in traumatized females, but not males
GG: Normal variant of snp associated with PTSD, hyperarousal in females.
rs2267013AA220.0 (1.2)77.14BCRAA: normal
AG: 1.3x increased risk for depression
GG: 1.3x increased risk for depression
rs2254958TT
AA
20.0 (2.5)21.88EIF2AK2CC: 1.61x increased risk for Alzheimer's
CT: 1.24x increased risk for Alzheimer's
TT: common
rs2243250CC50.0 (2.0)65.06IL4CC: normal
CT: 0.6x decreased risk for myocardial infarction if younger than 50
TT: 0.33x decreased risk for myocardial infarction if younger than 50
rs2243093TT170.0 (3.4)72.57GP1BA
rs2240340AA
TT
10.0 (0.0)16.85PADI4AA: increased risk for RA
AG: increased risk for RA
GG: average
rs2237717CT7 (3.0)49.75METTT: reduced abilities related to neurocognition and ability to recognize faces
rs2231142CC
GG
40.0 (3.5)78.46ABCG2AA: causes gout
AC: 1.74x increased gout risk; gefinitib takers 4x more susceptible to diarrhea
CC: normal
rs2230926TT60.0 (2.1)91.36TNFAIP3GG: 1.4x risk of rheumatoid arthritis
TT: common in complete genomics
rs2230600AA4 (1.9)70.04PTPN13
rs2230288GG
CC
10.0 (1.0)98.29GBAAA: Homozygous for E326K variant of GBA gene
AG: E326K variant in GBA gene
GG: common in clinvar
rs2230199CC
GG
190.0 (2.0)65.96C3CC: common
CG: 1.6x+ risk of ARMD
GG: 2.5x+ risk of ARMD
rs2229765AG15 (2.1)45.84IGF1RAA: Low IGF-1 level, linked to number of diseases
GG: Normal IGF-1 level
rs2229616GG
CC
180.0 (2.1)96.49MC4RAA: lower risk of metabolic syndrome
AG: lower risk of metabolic syndrome
GG: normal
rs2228000CT
AG
30.0 (1.0)35.88XPCCC: normal
CT: normal
TT: statistically significant, but slight, increase in bladder cancer risk
rs2227692CC70.0 (1.6)80.61SERPINE1CC: common in complete genomics
CT: 1.6x higher risk for diffuse gastric cancer
TT: 1.6x higher risk for diffuse gastric cancer
rs2187668GG
CC
60.0 (3.0)78.77HLA-DQA1AA: Autoimmune disorder risk (lupus, celiac disease) due to 2 HLA-DRB1*0301 alleles
AG: Somewhat increased autoimmune disorder (lupus, celiac disease) risk; 1 HLA-DRB1*0301 allele
GG: average
rs2145418TT
AA
10.0 (3.0)68.85GG: 9.2x increased thyroid cancer risk
GT: 5.0x increased thyroid cancer risk
TT: normal
rs2143340TT
AA
60.0 (2.3)72.39TTRAPCC: > 2x risk of dyslexia and poor reading performance
CT: increased risk of dyslexia and poor reading performance
TT: common
rs2107301CT
AG
120.0 (3.0)37.26VDRCC: normal risk
CT: ?
TT: 2.5x higher risk for prostate cancer
rs2075650AA190.0 (2.0)73.70TOMM40AA: normal
AG: 2x higher Alzheimer's risk
GG: 4x higher Alzheimer's risk
rs2074356CC
GG
120.0 (2.2)99.22C12orf51CC: common in complete genomics
CT: 1.5x increased risk for esophageal squamous cell cancer in Han Chinese
TT: 2.2x increased risk for esophageal squamous cell cancer in Han Chinese
rs2072590GG
CC
20.0 (1.4)49.94LOC401022GT: 1.2x increased risk for ovarian cancer
TT: 1.4x increased risk for ovarian cancer
rs2071746TT220.0 (0.0)19.97HMOX1AA: normal
AT: normal
TT: may be part of gs124
rs2070676CG100.0 (2.0)21.77CYP2E1CC: normal
CG: carrier of one CYP2E1*1B allele
GG: CYP2E1*1B homozygote
rs2070672AA100.0 (2.0)91.35CYP2E1AA: normal
AG: carrier of one CYP2E1*7_-352A>G allele
GG: CYP2E1*7_-352A>G homozygote
rs2070075CC90.0 (3.0)92.11GALTCC: common in complete genomics
rs2069526GT150.0 (0.0)5.95CYP1A2GG: CYP1A2*1K_-739T>G homozygote
GT: carrier of one CYP1A2*1K_-739T>G allele
TT: normal
rs2066847DD160.0 (4.0)95.55NOD2CC: 35x higher risk for Crohn's disease
GG: common on affy axiom data
rs2066845GG160.0 (4.0)96.56NOD2CC: ~35x higher risk for Crohn's disease
CG: 3x higher risk for Crohn's disease
GG: common in complete genomics
rs2066844CC160.0 (4.0)92.26NOD2CC: common in complete genomics
CT: 3x higher risk for Crohn's disease
TT: ~35x higher risk for Crohn's disease
rs2066843CT16 (2.0)37.07NOD2TT: 4.09x higher risk for Crohn's disease
rs2059693CC20.0 (1.6)49.37INHACC: normal
CT: 1.3x increased risk for testicular cancer
TT: 1.6x increased risk for testicular cancer
rs2046210CC
GG
60.0 (1.6)41.34CT: 1.4x increased breast cancer risk
TT: 1.6x increased breast cancer risk in certain women
rs2020912TT20.0 (2.5)99.00MSH6CT: unclear if associated with hereditary nonpolyposis colorectal cancer (HNPCC5)
TT: common in clinvar
rs2011077AG
CT
50.0 (3.0)35.04FGFR4AA: Normal risk of developing prostate cancer, BPH, and metastatic prostate cancer
GG: 6.2x increased risk of developing prostate cancer, a 3x increased risk of developing BPH, and a 5.5x increased risk of developing metastatic prostate cancer
rs2004640TT70.0 (0.0)11.11IRF5GG: normal; 0.9x decreased risk for rheumatoid arthritis
GT: 1.4x increased risk for SLE
TT: 1.4x increased risk for SLE
rs1992660GG
CC
50.0 (0.0)19.34PTGER4AA: increased risk for Crohn's disease
AG: ?
GG: 0.72x decreased risk for Crohn's disease
rs1954787CC110.0 (2.0)30.64GRIK4CC: ~10% more likely to respond to citalopram
CT: normal risk
TT: ~10% less likely to respond to citalopram
rs1861494TT12 (1.5)51.41IFNGCT: IBD risk
rs1859962GT170.0 (2.3)50.78CASC17GG: 1.28x increased risk for prostate cancer
GT: normal risk
TT: normal risk
rs1859345CC50.0 (0.0)9.35SPOCK1CC: slightly earlier age at menarche
CT: normal
TT: normal
rs1805137TT60.0 (5.0)99.87PEX7AA: Rhizomelic Chondrodysplasia Punctata Type 1
AT: Rhizomelic Chondrodysplasia Punctata Type 1 carrier
TT: common in clinvar
rs1805008CC160.0 (3.0)87.71MC1RCC: common in clinvar
CT: None
TT: ~7-10x higher likelihood of red hair
rs1805007CC160.0 (3.2)87.55MC1RCC: normal risk
CT: increased response to anesthetics
TT: increased response to anesthetics; 13-20x higher likelihood of red hair
rs1804197CC50.0 (2.0)93.98APCAA: Increased risk of familial colorectal cancer and Asperger's syndrome
AC: Increased risk of familial colorectal cancer and Asperger's syndrome
CC: common in complete genomics
rs1803274AA
TT
30.0 (0.0)4.08BCHEAA: possible increased Alzheimer's risk
AG: possible increased Alzheimer's risk
GG: normal
rs1801394AG50.0 (2.0)47.03MTRRAA: normal
AG: normal
GG: 1.4x higher risk for meningiomas
rs1801272TT
AA
190.0 (2.0)94.80CYP2A6AA: Reduced CYP2A6 metabolism; impaired nicotine metabolism?
AT: Reduced CYP2A6 metabolism; impaired nicotine metabolism?
TT: common in clinvar
rs1801253CG100.0 (1.1)41.01ADRB1CC: responds well to bucindolol; may also depend on rs1801252
CG: depends on [[rs1801252]]
GG: depends on [[rs1801252]]
rs1801157GG
CC
100.0 (1.4)56.99CXCL12AA: 1.4x higher risk for breast cancer
AG: 1.4x higher risk for breast cancer
rs1801155TT50.0 (3.0)99.81APCAA: risk of colon cancer
AT: risk of colon cancer
TT: common in complete genomics
rs1801133CC
GG
10.0 (3.0)44.95MTHFRCC: Common genotype: normal homocysteine levels
CT: 1 copy of C677T allele of MTHFR = 60% efficiency in processing folic acid = could have somewhat elevated homocysteine and low B12 and folate levels, risk of poor detoxing, neurodegenerative issues, chemical sensitivities, coronary artery disease, depression, cancer
TT: homozygous for C677T of MTHFR = 10-20% efficiency in processing folic acid = high homocysteine, low B12 and folate levels, poor detoxing, neurodegenerative issues, chemical sensitivities, coronary artery disease, depression, cancer
rs1800860AG100.0 (1.0)41.01RETAA: 10% smaller kidneys as newborns
AG: 10% smaller kidneys as newborns
GG: Normal sized kidneys as newborns
rs1800795CG70.0 (2.0)46.09IL6CC: less IL6; certain risks, see details
CG: complex; see details
GG: more IL6; certain risks, see details
rs1800730AA60.0 (2.6)96.44HFEAA: common in clinvar
AT: carrier for a mild form of hemochromatosis
TT: affected by a mild form of hemochromatosis
rs1800709CC
GG
170.0 (2.0)99.75BRCA1CC: normal
CT: possible predisposition to breast cancer
TT: predisposition to breast cancer?
rs1800693TT12 (1.4)37.88TNFRSF1AAA: common/normal
AG: slight (1.2x) increase in risk for multiple sclerosis
GG: slight (1.4x) increase in risk for multiple sclerosis
rs1800566CC
GG
160.0 (3.1)63.31NQO1CC: common in clinvar
CT: Higher cancer risk
TT: Benzene toxicity; cancer risks
rs1800562GG60.0 (4.0)92.74HFEAA: Two copies of C282Y, likely affected by hemochromatosis which may be serious if male or post-menopausal.
AG: One copy of C282Y, carrier of hemochromatosis, likely unaffected unless also H63D carrier.
GG: Not a C282Y hemochromatosis carrier.
rs1800546GG
CC
90.0 (3.5)99.41ALDOBCG: Carrier for high risk of of hereditary fructose intolerance (HFI)
GG: normal
rs1800544CC100.0 (2.0)46.90ADRA2AGG: cognitive effects?
rs1800462GG
CC
60.0 (3.5)99.81TPMTCC: incapable of detoxifying
CG: detoxifying ability may be diminished
GG: normal for 23andMe
rs1800460GG
CC
60.0 (3.5)94.78TPMTAA: incapable of detoxifying byproducts of certain drugs
AG: (TPMT*3B) impaired drug metabolism
GG: normal
rs1800454GG
CC
60.0 (1.5)73.46TAP2AA: affected
AG: carrier
GG: normal
rs1800443TT110.0 (3.5)99.69DRD4GG: Rare DRD4 polymorphism
GT: Uncommon DRD4 polymorphism
TT: common in clinvar
rs1800278AA
TT
X0.0 (0.5)39.06DMDAA: common in clinvar
rs1800098GG70.0 (3.0)99.49CFTRCG: unaffected carrier of an allele associated with vas deferens condition?
GG: common in clinvar
rs1800058CC110.0 (1.5)96.04ATMCC: common in complete genomics
CT: very slightly increased risk (1.05) for breast cancer
TT: 1.5x increased risk for breast cancer
rs1800056TT110.0 (1.5)97.37ATMCC: 1.5x increased risk for breast cancer
CT: very slightly increased risk (1.05) for breast cancer
TT: normal
rs1800054CC110.0 (1.5)97.87ATMCC: common on affy axiom data
CG: very slightly increased risk (1.05) for breast cancer
GG: 1.5x increased risk for breast cancer
rs1800012GG
CC
170.0 (2.0)70.32COL1A1GG: normal
GT: normal
TT: possibly reduced risk of anterior cruciate ligament ruptures
rs1799971AA60.0 (2.6)73.43OPRM1AA: normal
AG: stronger cravings for alcohol. if alcoholic, naltrexone treatment 2x more successful
GG: more pain
rs1799966AA
TT
170.0 (2.0)44.77BRCA1AA: common in clinvar
GG: increased risk for breast cancer
rs1799954CC130.0 (2.0)99.56BRCA2CC: common in complete genomics
rs1799950AA
TT
170.0 (2.0)87.93BRCA1AA: normal breast cancer risk
AG: increased breast cancer risk
GG: increased breast cancer risk
rs1799945CC60.0 (4.0)75.13HFECC: Not a H63D hemochromatosis carrier.
CG: One copy of H63D, carrier of hemochromatosis, likely unaffected unless also C282Y carrier.
GG: Two copies of H63D, likely affected by mild form of hemochromatosis
rs1799944AA130.0 (2.0)92.38BRCA2AA: common in complete genomics
rs1799941GG170.0 (1.5)59.46SHBGAA: Sex Hormone-Binding Globulin levels are 0.4 standard deviations higher
AG: Sex Hormone-Binding Globulin levels are 0.2 standard deviations higher
rs1799930GG80.0 (2.8)49.78NAT2AA: Increased risk of hearing loss
AG: Increased risk of hearing loss
GG: Normal
rs1799913AC
GT
11 (1.1)48.87TPH1CC: Hispanics may be at increased risk of heroin addiction.
rs1799807AA
TT
30.0 (4.0)96.68BCHEAA: Typical BuChE
AG: Heterozygous for "atypical" BuChE
GG: Homozygous for "atypical" BuChE; see warning re drug (incl. anesthetic) use
rs1799750II11 (1.5)25.52MMP1GG: in breast cancer patients, slightly higher risk for poorer prognosis
rs1784931AC110.0 (1.0)47.29SORL1AA: normal
AC: normal
CC: reduced risk for Alzheimers?
rs1736557GG10.0 (1.1)86.14FMO3AA: normal?
AG: unlikely to be associated with trimethylaminuria unless as a carrier (if that)
GG: common in clinvar
rs1691053AA
TT
50.0 (2.0)79.49AA: common in complete genomics
AG: Increased risk of developing prostate cancer
GG: Increased risk of developing prostate cancer
rs1571801CC
GG
90.0 (1.5)57.14DAB2IPAA: >1.36x risk for prostate cancer
AC: 1.36x risk for prostate cancer
CC: average
rs1566439AG
CT
16 (2.0)47.56NLRC5CC: associated with higher HDL cholesterol
CT: associated with higher HDL cholesterol
rs1554973TT90.0 (2.0)54.54TLR4CC: increased risk for chorionic plate inflammation
CT: increased risk for chorionic plate inflammation
TT: normal
rs1545985GG30.0 (0.0)13.89FYCO1AA: normal risk
AG: somewhat higher risk for prostate cancer
GG: somewhat higher risk for prostate cancer
rs1545843GG120.0 (1.4)26.21AA: 1.4x increased risk for depression (for those under 55)
GG: normal
rs1544410AG
CT
120.0 (2.0)46.52VDRAA: Increased risk of low bone mineral density disorders
AG: Intermediate risk of low bone mineral density disorders
GG: Decreased risk of low bone mineral density disorders
rs1532268GG
CC
50.0 (2.0)42.14MTRRAA: increased risk
GG: normal
rs1494558AA
TT
50.0 (0.0)12.73IL7RAA: common in clinvar
rs1494555CC
GG
50.0 (0.0)11.77IL7RCC: common in clinvar
rs1447295CC80.0 (1.7)79.40LOC727677AA: 1.7x increased risk of prostate cancer
AC: 1.4x increased risk of prostate cancer
CC: normal
rs1414334GGX (2.0)28.45HTR2CCC: associated with metabolic syndrome when taking antipsychotics
rs1393350GG110.0 (3.0)57.42TYRGG: common on affy axiom data
rs1360780CC60.0 (2.1)48.28FKBP5CC: normal
CT: 1.3x increased risk for depression
TT: 1.3x increased risk for depression
rs1360517GG
CC
90.0 (1.5)86.09AG: Higher susceptibility for AIDS
rs1333049GG90.0 (4.0)28.57CC: 1.9x increased risk for CAD
CG: 1.5x increased risk for CAD
GG: normal
rs1333048AA90.0 (2.1)26.15AA: normal
AC: 1.3x increased coronary artery disease risk
CC: 1.5x increased coronary artery disease risk; 2x increased periodontitis risk
rs1333040CC90.0 (0.0)18.22CDKN2BASCC: normal
CT: 1.24x increased myocardial infarction risk, 1.29x increased aneurysm risk
TT: 1.52x increased myocardial infarction risk, 1.67x increased aneurysm risk
rs1327328CC
GG
130.0 (0.0)17.22CC: normal
CT: normal
TT: 1.7x increased risk for multiple sclerosis
rs1268524AA
TT
10.0 (0.2)49.28SLAMF6
rs1265159CT
AG
60.0 (2.5)33.02POU5F1CC: normal
CT: ~5x increased risk of psoriasis
TT: psoriasis risk for Chinese?
rs1243168CC
GG
14 (2.3)65.98SERPINA1
rs1233478CC
GG
6 (2.1)68.14
rs1219648AA100.0 (2.1)35.88FGFR2AG: 1.20x risk for breast cancer
GG: 1.64x risk for breast cancer
rs1169300GG120.0 (2.0)47.18HNF1AAA: ~2x increased lung cancer risk
AG: ~1.5x increased lung cancer risk
GG: normal
rs1154155TT140.0 (2.5)70.80TRAGG: 2.5x increased risk for narcolepsy
GT: 1.94x increased risk for narcolepsy
TT: normal
rs1143679GG160.0 (3.0)78.78ITGAMAA: >1.78x increased risk for SLE
AG: 1.78x increased risk for SLE
GG: normal
rs1142345AA
TT
60.0 (3.5)93.97TPMTAA: common in clinvar
AG: TPMT*3C . impaired drug metabolism
GG: possibly incapable of detoxifying
rs1135824AA
TT
220.0 (4.5)99.94AA: normal
AG: One copy of CYP2D6*3B non-functioning variant.
GG: Two copies of CYP2D6*3B non-functioning variant
rs1127354AC20 (3.2)13.41ITPAAA: causitive. Ribavirin-induced anemia iRibavirin-induced anemia during anti-hepatitis C virus therapy
CC: common in clinvar
rs1076560CC110.0 (2.0)69.51DRD2AA: influences working memory
AC: 1.3x increased risk for alcoholism
CC: normal
rs1064395GG190.0 (2.1)68.32NCANAA: Having the A allele at this SNP makes your risk for developing bipolar disorder or schizophrenia higher.
AG: Having any copies of A at this SNP heightens your risk for bipolar disorder and schizophrenia.
GG: Normal risk of bipolar disorder or schizophrenia
rs1064039GG
CC
200.0 (2.0)56.18CST3AA: Higher risk for age-related macular degeneration; slightly higher Alzheimers risk in Caucasians but not Asians
AG: slightly higher risk for Alzheimers in Caucasians but not Asians
GG: common in clinvar
rs1061646TT
AA
160.0 (0.0)11.47FANCACC: 1.16x increased risk for breast cancer
CT: 1.08x increased risk for breast cancer
TT: normal risk
rs1057868CC70.0 (1.6)53.69PORCC: normal
CT: normal
TT: 1.6x higher overall CYP3A activity
rs1050829AA
TT
X0.0 (2.2)39.22G6PDAA: G6PD Type B
AG: G6PD Type A/B
GG: G6PD Type A
rs1050828GG
CC
X0.0 (4.0)39.64G6PDAA: G6PD deficiency
AG: G6PD deficiency carrier
GG: common in clinvar
rs1049550TT
AA
100.0 (0.0)17.15ANXA11CC: normal
CT: 0.62x reduced risk for sarcoidosis
TT: 0.62x reduced risk for sarcoidosis
rs1049296CC30.0 (1.2)70.88TFCC: C1 subtype of transferrin; common in clinvar
CT: Heterozygote carrying both C1 and C2 transferrin subtypes; very slightly higher risk for Alzheimers
TT: C2 transferrin subtype; very slightly higher risk for Alzheimers
rs1047286CC
GG
190.0 (1.7)66.77C3CC: common in clinvar
CT: 1.3x increased risk for age-related macular degeneration
TT: 1.7x increased risk for age-related macular degeneration
rs1045485CG2 (2.0)19.97CASP8CC: Reduced Risk of Breast Cancer
GG: but the rare allele is protective
rs1044396CT
AG
20 (2.0)48.56CHRNA4CC: Increased risk of Nicotine dependence among males
rs1042838GG
CC
110.0 (3.0)72.98PGRGG: normal risk
GT: 1.28x risk for endometrial ovarian cancer; overlaps with rs608995
TT: 1.42x risk for endometrial ovarian cancer; overlaps with rs608995
rs1042713GG50.0 (1.7)36.76ADRB2AA: 1.7x increased risk that pediatric inhaler use may make asthma worse
AG: 1.3x increased risk that pediatric inhaler use may make asthma worse
GG: normal
rs1042602AA110.0 (0.0)10.39TYRAA: associated with the absence of freckles
AC: None
CC: None
rs1041981CC60.0 (2.0)44.96LTAAA: Higher myocardial infarction risk
CC: normal
rs1027557AA
TT
120.0 (0.1)60.71AG: heterozygosity seems common
rs1021737GG10.0 (3.0)51.25CTHGG: common in clinvar
TT: significantly higher plasma total homocysteine concentration
rs1007371AT2 (1.2)17.61CTNNA2TT: rare genotype.
rs1006737GG120.0 (1.7)47.70CACNA1CAA: increased risk of Bipolar disorder
rs997669AG
CT
190.0 (1.1)44.92CCNE1AA: 1.18x higher risk for breast cancer
AG: ?
GG: normal risk
rs992037TT60.0 (0.0)12.84PARK2CC: lowest lysine values
CT: intermediate lysine values
TT: highest lysine values
rs975278GG
CC
20.0 (1.5)62.12SERPINE2AA: 1.5x higher risk for emphysema, higher in smokers
GG: normal
rs966423TT2 (2.0)31.93DIRC3CC: Possible elevated thyroid cancer risk
CT: Possible elevated thyroid cancer risk
rs966221CT
AG
50.0 (1.5)47.24PDE4DCC: 1.5x increased stroke risk certain populations
CT: 1.5x increased stroke risk
TT: normal
rs964201GG10.0 (2.0)98.62ASPMGG: common in complete genomics
rs964184CC110.0 (2.2)73.70ZNF259GG: increased risk of hypertriglyceridemia
rs931127AG110.0 (2.1)50.55SIPA1AA: 2.15x more likely positive lymph node
GG: more favorable
rs910873GG200.0 (4.0)88.19PIGUAA: 3x increased risk of melanoma
AG: 1.7x increased risk of melanoma; increased risk of squamous cell carcinoma
GG: normal
rs887829GG
CC
20.0 (2.0)45.18UGT1A10AA: Higher levels of serum bilirubin, associated with lower risk for coronary artery disease
GG: common
rs887391TT19 (1.5)56.28LOC100505495CC: Lower prostate cancer risk?
rs867186AG200.0 (0.0)17.85PROCRAA: normal risk for VTE
AG: EPCR H3 haplotype; reduced or increased risk of VTE?
GG: EPCR H3 diplotype; reduced or increased risk of VTE?
rs855913GG
CC
70.0 (2.1)88.97GG: common in complete genomics
GT: reduced survival with ALS
TT: reduced survival with ALS
rs806380AG60.0 (2.1)43.08CNR1AA: Normal genotype. slightly higher odds of cannabis dependence
GG: uncommon. lowest odds of cannabis dependence
rs806368CT6 (2.5)34.00CNR1CC: Associated with Alcohol Dependence; associated with nicotine dependence (female)
rs798766CC4 (1.0)64.05TACC3TT: Increased susceptibility urinary bladder cancer
rs793862AG60.0 (2.0)41.01DCDC2AA: 3-5x dyslexia risk
AG: increased dyslexia risk
GG: common
rs766173TT
AA
130.0 (2.0)92.60BRCA2TT: common in complete genomics
rs751229TT
AA
1 (2.0)36.03DISC1
rs725613CC
GG
160.0 (0.0)15.22CLEC16AAA: 1.2x increased type-1 diabetes risk; 1.2x increased multiple sclerosis risk
AC: 1.2x increased type-1 diabetes risk; 1.2x increased multiple sclerosis risk
CC: normal
rs679620AG
CT
11 (1.0)48.25MMP3GG: higher risk for Achilles tendinopathy?
rs662799AA110.0 (2.0)84.91APOA5AA: normal
AG: 1.4x higher early heart attack risk; less weight gain on high fat diets
GG: 2x higher early heart attack risk; less weight gain on high fat diets
rs660895AA60.0 (2.5)64.62AA: normal
AG: possibly at 4x higher risk of [[rheumatoid arthritis]]
GG: 6x higher risk of rheumatoid arthritis
rs657152CC9 (2.0)38.63ABOTT: Multiple risks, see details
rs619203CC
GG
60.0 (1.5)56.67ROS1CG: increases susceptibility to Myocardial Infarction 1.15 times
GG: None
rs602662AG19 (2.0)49.97FUT2AA: Higher vitamin B12 levels
GG: Lower vitamin B12 levels
rs591058CT11 (1.0)48.22MMP3CC: higher risk for Achilles tendinopathy?
rs582757CT6 (1.2)37.64TNFAIP3CG: candidate causal variant of psoriasis
rs569108CT
AG
110.0 (0.0)6.71MS4A2CC: ?
CT: 3x risk of predisposition to childhood asthma in a Japanese population
TT: normal
rs518147CC
GG
X0.0 (0.0)18.16HTR2CCC: less weight gain if taking olanzapine
CG: normal
GG: normal
rs503362GG110.0 (0.1)56.93PGR
rs498872CC
GG
110.0 (1.4)52.16PHLDB1CT: 1.2x higher risk for glioma development
TT: 1.4x higher risk for glioma development
rs498422AA
TT
6 (1.4)86.41C6orf10AC: slightly higher risk for infertility in Chinese men
CC: slightly higher risk for infertility in Chinese men
rs471767AA110.0 (0.1)49.78PGR
rs429358CT190.0 (1.2)23.86APOECC: one of 2 snps relevant to classifying APOE genotype
CT: >3x increased risk for Alzheimer's; 1.4x increased risk for heart disease
TT: common
rs402710CT5 (1.9)43.71CLPTM1LCC: Common, but higher lung cancer risk ?
rs401681TT50.0 (1.5)17.83CLPTM1LCC: ~1.2x increased risk for several types of cancer
CT: ~1.2x increased risk for several types of cancer
TT: normal
rs380390CG10.0 (2.1)45.40CFHCC: increased risk for ARMD
CG: None
rs365990AG14 (1.1)44.01MYH6GG: risk genotype
rs356220CT4 (1.5)46.17TT: increased risk of Parkinson's Disease
rs324650AA70.0 (0.1)28.18CHRM2
rs324420CC10.0 (2.5)62.93FAAHAA: significantly increased risk for substance use disorders
AC: normal
CC: normal
rs283413GG
CC
40.0 (2.5)97.99ADH1CGG: normal
GT: 3x higher risk for PD
TT: 3x higher risk for PD
rs279858AG
CT
40.0 (2.1)48.22GABRA2AA: None
AG: None
GG: apparently more prone to alcoholism
rs261332GG150.0 (2.0)62.74LIPCAA: associated with higher HDL cholesterol
AG: associated with higher HDL cholesterol
GG: common in complete genomics
rs258322CC
GG
16 (3.0)77.96CDK10TT: 2x increased risk of Melanoma
rs251124CT5 (0.1)30.47VCAN
rs234706GG21 (2.5)46.71CBSAA: 0.50 reduced risk of cleft lip / palate, 0.51 reduced risk of non-Hodgkin lymphoma. Increased responsiveness to homocysteine-lowering effects of folic acid.
AG: 0.94 reduced risk of cleft lip / palate
rs210138AA60.0 (2.7)63.82BAK1AA: common in complete genomics
GG: Testicular Cancer
rs201571CC20 (2.0)20.85TT: more likely to go bald
rs198846GG60.0 (3.0)74.91HIST1H1T
rs187238CG110.0 (2.0)39.32IL18CC: hypertension not a risk factor for sudden cardiac death
CG: hypertension not a risk factor for sudden cardiac death
GG: hypertension increases risk 3.75x for sudden cardiac death
rs144848TT
AA
130.0 (2.0)51.35BRCA2GG: 1.3x increased risk for breast cancer
GT: possible increased risk for breast cancer
TT: normal
rs131702GT220.0 (0.2)27.26BCRTT: normal risk
rs34330CC120.0 (1.3)55.60CDKN1BCC: normal risk for endometrial/breast cancer
CT: 1.3x higher risk for endometrial cancer (in Chinese women)
TT: 1.2x higher breast cancer risk; 1.3x higher risk for endometrial cancer (in Chinese women)
rs26722CC50.0 (2.1)91.67SLC45A2CC: normal
CT: perhaps darker eye, hair, skin
TT: darker eye, hair, skin color
rs17580AA
TT
140.0 (2.5)94.29SERPINA1AA: common in complete genomics
AT: carrier of a variant in Alpha-1 Antitrypsin Deficiency
TT: a slightly reduced functionality form of Alpha-1 Antitrypsin Deficiency
rs17571CC
GG
110.0 (2.1)85.35CTSDCC: common on affy axiom data
TT: rare and doesn't seem helpful
rs17435AAX0.0 (2.0)24.61MECP2AA: normal
AT: 1.4x increased risk for lupus
TT: 1.4x increased risk for lupus
rs16942AA
TT
170.0 (2.0)44.63BRCA1AA: common in clinvar
AG: slightly increased risk for breast cancer
GG: increased risk for breast cancer
rs13706GG170.0 (2.0)78.27CDC6AA: Decreased risk for certain cancers
GG: common in complete genomics
rs8702GG
CC
140.0 (0.0)10.14KLC1CC: average
CG: ?
GG: 0.2x risk for MS
rs6313CT
AG
130.0 (2.1)46.96HTR2ACC: higher risk for RA
CT: higher risk for RA
TT: depression, panic, stress response
rs6277CT
AG
110.0 (2.0)46.95DRD2CC: 1.6x higher schizophrenia risk
CT: 1.4x higher schizophrenia risk
TT: normal schizophrenia risk, learns NoGo faster
rs6265GG
CC
110.0 (3.0)66.25BDNFAA: introversion; depression resistant; impaired motor skills learning
AG: impaired motor skills learning?
GG: common/normal
rs6232AA
TT
50.0 (2.1)90.86PCSK1AA: common in complete genomics
AG: obesity and insulin
GG: obesity and insulin
rs6046CC
GG
130.0 (2.8)77.71F7CC: common in clinvar
TT: better blood pressure, lower risk of myocardial infarction
rs6025GG
CC
10.0 (3.5)96.06F5AA: 9x risk of thrombosis
AG: Prone to thrombosis
GG: normal/common
rs5370GG60.0 (1.2)60.30EDN1GG: common
GT: possibly lower HDL cholesterol in women
TT: possibly lower HDL cholesterol in women
rs5361AA
TT
10.0 (2.5)81.53SELEAA: normal risk
AC: normal risk
CC: 4x increased risk for recurrent venous thromboembolism.
rs5352GG
CC
130.0 (3.5)97.74EDNRBAA: Hirschsprung disease?
AG: probably Hirschsprung disease carrier
GG: common
rs5326GG
CC
5 (1.0)70.88DRD1AG: possible psychiatric risks
rs5275CC
GG
10.0 (0.0)12.49PTGS2CC: 0.68x decreased risk for bladder cancer
CT: 0.68x decreased risk for bladder cancer
TT: normal
rs5186AA30.0 (4.0)52.04AGTR1AA: normal risk
AC: ~1.4x increased risk of hypertension
CC: 7.3x increased risk of hypertension
rs5082TT
AA
10.0 (2.5)40.19APOA2CC: saturated fat contributes to obesity
CT: normal risk
TT: normal risk
rs4994TT
AA
80.0 (2.0)83.33ADRB3CC: 2x higher risk in certain women for cardiac events
CT: 2x higher risk in certain women for cardiac events
TT: normal
rs4680AG220.0 (2.5)50.13COMTAA: (worrier) advantage in memory and attention tasks
AG: multiple associations, see details
GG: (warrior) multiple associations, see details
rs4673CC
GG
160.0 (2.0)44.02CYBACC: normal
CT: normal
TT: 3.9x increased risk for cerebral ischemia
rs4343AG17 (2.0)48.84ACEAA: usually the ACE Alu insertion; better endurance vs strength;
GG: usually the ACE Alu deletion; better strength vs endurance;
rs3077TT
AA
60.0 (2.0)64.43HLA-DPA1CC: 1.8 times higher odds of having chronic hepatitis B
TT: common in complete genomics
rs699TT
AA
10.0 (2.0)30.24AGTCC: increased risk of hypertension
CT: increased risk of hypertension
TT: normal risk of hypertension
rs268AA80.0 (2.1)96.49LPLAA: common in clinvar
AG: 3X increased risk for venous thromboembolism
GG: 3X+ increased risk for venous thromboembolism